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ABSTRACT 
Abstract of thesis entitled: 
Altered expression of the growth and transformation-suppressor PML 
Submitted by Chin Wai, supervised by Prof.John Y. H. Chan, Ph.d. 
For the degree of Master of Philosophy in medical sciences 
At the Chinese University of Hong Kong in July 1999 
The promyelocytic leukemia (PML) gene, which encodes a 
transformation and growth suppressor, was first identified at the 
chromosomal translocation break point of acute promyelocytic 
leukemia. To elucidate if PML may be involved in other neoplasias 
such as the hepatocellular carcinoma (HCC) and lung cancers, 
the expression of PML was analyzed by immunohistochemical 
staining. Our studies demonstrated that increases of 5-10-fold 
expression of PML protein in the POD {PML-Oncogenic Domain) 
structure were found in a considerable number of HCC (50-60%), 
whereas in other HCC the expression was low. PML also 
showed enhanced expression and cytoplasmic localization in 
some HCC and in chronic hepatitis tissues which were associated 
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with cirrhosis. However, in the adenocarcinoma of colon 
metastasis to the liver, the expression of PML was from moderate 
to low. Increased expression of PML protein was found in 
adenocarcinomas (ADC) and squamous cell carcinomas (SCC) of 
the lung, but was undetectable in small cell lung cancer (SCLC). 
In addition, PML expression progressively decreased from the 
periphery to the center of the tumors, which may be associated 
with altered transform-phenotypes or apoptosis. Double staining 
with the proliferation marker Ki-67 indicated that PML was 
expressed in Ki-67-negative non-proliferative cells, while double 
staining with the macrophage specific marker KP-1 indicated that 
tumor-associated macrophages were devoid of PML expression, 
in contrast to the non-tumorigenic tissues. Cell culture 
experiments showed that HeLa cells transfected with PML 
showed lower growth rate, different morphology and more 
sensitive to cisplatin induced cell death. The altered expression 
of PML indicates that this nuclear protein may play an important 
role in cellular response to stress and inflammation, as well as in 
compensatory cell growth. PML may act as an useful marker for 
hyperplasia and hypertrophy in cancer development. The specific 
viii 
inactivation of PML in SCLC also suggests that this alteration may 
be an obligatory step in the tumorigenesis of SCLC. 
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INTRODUCTION 
Hepatocellular carcinoma. HCC accounts for approximately 
85% of primary malignant tumor of the liver and HCC also shows 
marked geographic variation in incidence (1,2). In Hong Kong 
and South"Eastern Asia, with an incidence of 25-35/100,000, it is 
one of the major cancers in this region, especially those with 
hepatitis B virus infection and/or liver cirrhosis. Epidemiological 
and experimental evidences have shown that the etiology of 
hepatocellular carcinoma (HCC), like other kinds of cancer, is 
multi-factorial and multi-stage (1-6). The risk factors for HCC may 
be divided into environmental factors including biological and 
chemical agents, and genetic factors. The major biological agents 
are the hepatitis viruses including the hepatitis B virus (HBV) and 
hepatitis C virus (HCV), and parasites such as the liver fluke 
which contributes to parasitic hepatitis. Chemical agents that 
contribute to HCC are: aflatoxin, nitrosannines, vinyl chloride， 
peroxisome proliferators and alcohol (1). Most of these agents 
either directly or indirectly induce mutations or alterations in DNA, 
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or act as promoters which facilitate the proliferation of 
hepatocytes and the fixation of DNA lesions. In addition, genetic 
factors such as metabolic disorders, DNA repair defects and 
altered susceptibility genes may also contribute to the 
development of HCC. Differential susceptibility to the 
development of liver cancers varies considerably among different 
rodent species and strains, while in humans, familial clustering of 
HCC have been described in Chinese and Alaskan natives (3). 
The evolution of HCC may be divided into several stages: 
genomic /DNA damage (initiation); chronic liver injury (promotion) 
which produces inflammation, cirrhosis and cell death; 
regeneration (promotion); adenomatous hyperplasia/dysplasia 
(progression), and HCC. Specific genetic and epigenetic changes 
including the differential expression of genes have been identified 
for some of these stages. In HCC, increased expression of 
growth-associated genes including c-myc, c-ras, c-fos, cyclin D1 
and c-jun while increased mutations or alterations in suppressor 
genes such as p53, p16 and Rb have been documented (1,4,6). 
It is hoped that the molecular studies will be informative in 
dissecting the multifactorial etiology of HCC, and in setting 
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priorities for the implementation of prevention and treatment. 
Lung cancers. In addition, lung cancer continues to be the most 
common neoplasm in the world accounting for 20 % of all cancers 
in men and 11 % in women (7-10). The major risk factors for 
lung cancer are cigarette smoking and increased air pollutants in 
our industrialized cities. In Hong Kong and mainland China, 
where increasing numbers of the population are tobacco users, 
and with less than desirable environmental conditions, cancers of 
the lung constitute one of the major malignant diseases. The 
overall 5-year survival rate for lung cancer in Hong Kong is below 
15% (10). Only one third of the patients are eligible for surgical 
resection with curative intent and among them, less than one third 
will be alive 5 years post-surgery. In the past decade, innovative 
approaches in diagnosis and therapy have been successful in 
treating a considerable number of neoplastic diseases, yet little 
progress has been made to significantly improve the prognosis of 
lung cancer. 
Recent molecular studies indicate that activation of proto-
oncogenes such as c-myc, L-myc, ras and erbB2 are often found 
in lung cancer (7-9). In addition, acquired genetic mutations 
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have been identified in a number of tumor suppressor genes 
including Rb, p53 and p16 (7,8). Hyper-methylation or modified 
levels of transcriptional factors may contribute to the depressed 
expression of tumor suppressor genes. However, enhanced 
levels of suppressor proteins resulting from increased stability of 
the protein, were also found in cancer cells that either contained 
the mutated gene, or when the protein was sequestered and 
inactivated by viral proteins. On the other hand, mutations in 
specific regions of the gene may contribute to the aberrant 
localization of the gene product (7,8). These molecular 
alterations have been postulated to contribute to the transformed 
phenotypes and the loss of growth control in different types of 
lung cancer. However, not all samples of lung cancer contain 
these mutations or aberrations, and it is believed that other 
suppressor genes or critical cellular-genes may also play a role in 
the multi-stage, multi-hit process of tumorigenesis (7). Although 
cytogenetic studies have indicated that chromosomal loci 3p21.3, 
1p，9p and chromosome 4 are frequently altered in carcinomas of 
the lung, the genes responsible at these loci are still unknown 
(7-9). 
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The role of suppressor gene PML in cancer. Disruptions of 
proto-oncogenes and oncosuppressor genes have been 
attributed to the pathogenesis of many neoplastic diseases 
(11-15). The PML gene encodes a growth and transformation 
suppressor, and has been identified at the non-random 
chromosomal translocation break point t(15;17)(q22;q12) of acute 
promyelocytic leukemia (APL) (16-22). This translocation event 
fuses the PML and the retinoic acid receptor-a (RARA) genes 
and encodes the PML- RARA and RARA-PML fusion proteins. 
PML-RARA apparently exerts a dominant negative effect in cells 
by inactivating the normal functions of PML and retinoic acid X 
receptor (RXR) proteins. PML is a nuclear phosphoprotein which 
has been shown to inhibit cell growth and the transformed 
phenotypes of tumor cells (23-33). PML has also been found to 
accumulate at the border of a nuclear structure, namely the 
nuclear bodies (NB) or PML Oncogenic Domain (POD) (28,33). 
In APL cells, the PML- RARA fusion protein was found to 
accumulate into aberrant microstructures and is able to delocalize 
some other nuclear proteins. Thus, PML is a transcriptional 
factor that has been considered to play a crucial role in the 
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pathogenesis of APL. Significant increase in PML nuclear bodies 
and a non-aggregated soluble form were found in cells progress 
through G1 and S phase of the cell cycle (18). PML is also a 
member of a novel family of ring-finger proteins and is structurally 
related to enzymes expressing DNA repair and DNA 
recombination activities (15-17). PML co-localized with several 
proteins including the Sp-100, NDP55, PIC 1，lnt-6 and possibly 
others in the POD structure (25-28). In addition, evidence has 
been documented that PML may play a role in viral replication 
(34-37). During adenovirus infection, the immediate early viral 
proteins E1B 55 kDa and E4-ORF3 11 kDa are targeted to the 
POD structure (34,35). The immediate-early protein (Vmw110) 
of the herpes simplex virus (HSV) could also interact with PML 
(36) while the Epstein-Barr virus (EBV) encoded protein EBNA-5 
has been shown to co-localized with PML in the POD structure in 
lymphoblastoid cells (37). PML was found to be essential for 
multiple apoptotic pathways and that mice with PML homozygous 
deletion were protected from DNA-damage induced cell death 
(38,39). However, the precise function of PML and the POD 
structure is also unclear. One hypothesis put forth by Maul and 
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co-workers (33) is that the nuclear bodies or POD may represent 
storage sites of certain matrix proteins readily accessible 
throughout the chromatin in response to stress or other effectors 
that induce global nuclear changes. Thus, PML may act as a 
matchmaker to recruit or sequester other proteins in or out of the 
POD. 
Although reports on PML involving in other cancers have been 
documented (27-29)，the precise role of PML in regulating cell 
growth, and the transformed phenotypes of other neoplasias 
including the hepatocellular carcinomas (HCC) and lung cancer is 
still unclear. The PML gene displays an altered expression 
pattern in many types of cancers (27-29). A report by Koken et al 
(27) indicated that human epithelial tumors show a gradual 
increase of PML levels as the lesion progresses from dysplasia to 
carcinoma. However, when malignant cells turn invasive, they 
appeared to lose PML expression. On the other hand, Terris and 
co-workers (28) documented that enhanced PML expression was 
associated with inflammation and cell proliferation. We have 
previously shown the optimal expression of PML in the POD 
structure is at G1 arrest (40). Nevertheless, PML may play an 
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important role in the loss of growth control and in the oncogenesis 
of many cancers. 
Our laboratories are interested in the etiology, diagnosis and 
treatment of neoplastic diseases including HCC (6,41). To 
elucidate if PML may resemble other oncosuppressor genes such 
as the p53, and Rb, we examined the expression of PML protein 
in human tissues of HCC, hepatitis, cirrhosis, liver abscess and 
secondary liver cancers. We have previously reported on the 
cell cycle regulation of DNA damage-induced expression of PML 
(40). To determine if PML may be involved in lung cancer, we 
analyzed PML expression in lung cancer tissues including small 
cell lung cancer (SCLC), adenocarcinoma (ADC) and squamous 
cell carcinoma (SCC) by immunohistochemical staining. To further 
investigate the functional role of PML and it's possible mechanism 
on the control of cell growth. We also observed Hela-cell 
transfected with PML named Hela- PML by us about morphology, 
cell growth rate and response to anticancer drug. 
Principles of immunohistostaining methods. The ability to 
stain for specific cellular antigens or proteins in tissue sections is 
regarded as one of the most important recent developments in 
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anatomical pathology and research fields. While 
immunofluorescence methods were developed as early as 1941 
and have been very successful in some areas of pathology such 
as in the study of renal and skin diseases, they did not achieve 
widespread popularity among surgical pathologists. This lack of 
appeal resulted from two principle disadvantages, namely, their 
general unsuitability for use with conventional formalin-fixed, 
paraffin-embedded tissue and the poor cytomorphological detail 
obtained when immunofluorescence methods are applied to 
frozen sections. The need for fresh-frozen tissue was also a 
disadvantage as was the fact that the technique did not provide 
permanent preparations. The substitution of horseradish 
peroxidase for fluoresein-isothiocyanate as the label of the 
antibody made it possible to stain for the horseradish peroxidase. 
Through the addition of a suitable color substrate, a permanent 
colour reaction product was produced and this was visible by 
ordinary light microscopy. The concurrent development of the 
hybridoma technology to produce monoclonal antibodies provided 
the potential to stain for an expanding range of cellular antigens. 
Thus, immunohistochemistry rapidly entered into a new era of 
9 
expotential growth which has been called the brown 
revolution(43). 
1.) Immunofluorescence techniques: Fluorescene and 
phosphofluorescene is the emission of light following its 
absorption from a non-thermal source of energy such as 
ultraviolet or visible light. Phosphofluorescene persists after 
the source of energy or stimulating lights is present. The most 
commonly employed light source in fluorescence microscopy 
is a high-energy pressure mercury vapor lamp that supplies 
an intense ultraviolet radiation. Tungsten halogen, tungsten 
and xenon sources may also be used for fluorescence 
microscopy. The principle of the immunofluorescence staining 
procedure is based on the specific reaction of the 
fluorochrome-labeled antibody to antigen present in the 
substrate. The procedure can be performed in a wide variety 
of tissue and cell preparations. It is achieved by covering the 
substrate with fluorochrome-labeled antibodies, the specific 
antibody-antigen recognition allowing the binding of the 
fluorochrome-labeled antibodies to the sites where the 
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specific antigen is present. Unbound antibodies are washed 
away from the preparations with neutral buffer and the sites of 
antibody binding are identified by the stimulation of 
fluorescence in a fluorescence microscope. More than one 
antigen can thus be simultaneously identified in the same 
section or smear by using antibodies conjugated to different 
fluorochromes. The most commonly used 
immunofluorescence staining is the direct technique because 
of its speed and simplicity. Only washing is required after 
antibody labeling and no further reagents are needed, unlike 
enzyme immunohistochemical procedures. The major 
disadvantages of immunofluorescence techniques include the 
need for an expensive specialised microscope, the lack of 
permanency of the preparations and the poor visualisation of 
cytomorphological features. Furthermore, the 
auto-fluorescence of some biological tissues, particularly 
connective tissue, contributes to background fluorescence, 
posing additional difficulties in interpretation. The need for 
fresh-frozen tissue also limits the application of 
immunofluorescence methods in surgical pathology and 
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research field, where most specimens are routinely fixed in 
formalin and paraffin-embedded. Fluorescence labeling is 
impermanent and will fade with quenching. Also, the direct 
immunofluorescence technique requires greater 
concentrations of primary antibody having to be conjugated to 
a fluorochrome, adding to costs. 
2.) lmmunoenzyme techniques: By attaching an enzyme to a 
specific antibody, the enzyme activity can be used to induce a 
visible colour change in the substrate and chromogen, 
identifying the sites of localization of the antigen-enzyme 
complex within the tissue, i.e. the site of specific 
antibody-antigen reaction. Horseradish peroxidase was the 
prototype of the immunoenzyme method, but other enzyme 
systems such as glucose oxidase and alkaline phosphatase 
have also been successfully used. There are many 
commercial sources of enzyme-conjugated antibodies and 
chromogens, as well as kits, which contain matched reagents 
for the common types of multilayered immunoenzyme staining 
procedures. 
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A.) Direct lmmunoenzyme Techniques: The simplest of the 
immunoenzyme techniques utilizes an enzyme-conjugated 
antibody to bind an enzyme to antigens in the section. By 
incubating the section with an appropriate substrate such 
as hydrogen peroxide and a chromogen such as 
diaminobenzidine (DAB), a brown reaction product is 
produced and this is readily identifiable by light 
microscopy. While the direct immunoenzyme technique is 
simple, it is the least sensitive of the immunoenzyme 
techniques and is not the method of choice for routine 
diagnostic use. 
B.) Indirect and Bridge Immunoenzyme Techniques: Bridge 
techniques have the main advantage of increasing the 
sensitivity of the immunoenzyme stain by increasing the 
amount of reaction product deposited at the 
antigen-antibody reaction sites. Bridge techniques also 
increase the versatility of the procedure: a single 
conjugated antibody can be used with different primary 
antibodies to different antigens, eliminating the need to 
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conjugate each primary antibody separately. The indirect 
immunoenzyme procedure is a form of a bridge technique 
in that the primary antibody specific for the antigen being 
sought is located by an enzyme-conjugated secondary 
antibody. The primary antibody is incubated with the 
section; the section is then rinsed and incubated with an 
enzyme-conjugated secondary antibody which is specific 
for immunoglobulin from the species which was the source 
of the primary antibody. Incubation with an appropriate 
substrate and chromogen localizes the site of 
antibody-antigen reaction in the tissue section. This 
method allows the use of one enzyme-conjugated 
antibody preparation to bind to an unlimited variety of 
primary antibodies derived from a given species. 
Enzyme-anti-enzyme techniques are classic bridge 
techniques where anti-enzyme antibodies are used to form 
a bride between the primary antibody and the enzyme. 
This avoids the necessity of conjugating enzyme to 
antibodies, a procedure which can reduce antigen-binding 
avidity and is often technically difficult. The 
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peroxidase-anti-peroxidase system {PAP), introduced by 
Sternberger and associates in 1970，was reported to have 
a sensitivity 100- to 1000-fold greater than comparable 
conjugated techniques. In this procedure, the PAP 
complex, which is the tertiary reagent, consists of a 
soluble and stable preformed complex of antibody against 
horseradish peroxidase and horseradish peroxidase 
antigen. This immune complex typically consists of two 
antibody molecules and three horseradish peroxidase 
molecules in a cyclic to the antigen binds to the tissue 
antigen through its Fab portion. The secondary or bridge 
reagent, in turn, forms molecular bridge between the 
primary antibody and the immunoglobulin incorporated into 
the PAP complex. Both the primary antibody and PAP 
reagent have to be of the same species so that the bridge 
reagent, derived from a second species, can have 
specificity for the constant components of both primary 
and tertiary reagents. When anti-peroxidase is employed, 
endogenous peroxidase in the sections has to be blocked 
with hydrogen peroxide and methanol prior to 
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immunostaining. Non-specific binding is next blocked with 
diluted non-immune serum from the same species from 
which the bridging antibody was obtained. Addition of the 
bridging antibody will allow binding to the constant region 
of both the primary antibody as well as the antibodies in 
the PAP complex. Unbound bridging antibody is rinsed 
away before soluble PAP complexes are incubated with 
the section. The final step in the procedure is the reaction 
of the PAP complex with substrate and chromogen to form 
a product, which is visible by light microscopy, identifying 
the site of antigen in the tissue section. The high affinity 
binding between biotin and avidin has given rise to a 
sensitive immuno-staining procedure which is currently the 
most widely employed technique in diagnostic and 
research imm_histochemistry. Biotin is a low molecular 
weight vitamin which can be covalently linked to the 
primary antibody to produce a biotinylated conjugate. 
When this conjugate is added to the tissue section, it 
localizes to the sites of antigen. Avidin is an egg-white 
glycoprotein which has four avid binding sites for biotin. 
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Avidin is, therefore, used as a bridge between the 
components of the multilayered immunoenzyme stain. The 
addition of avidin, chemically conjugated to horseradish 
peroxidase, will allow tight binding of avidin to the 
biotinylated primary antibody, thus localizing to the site of 
antibody-antigen reaction in the tissue section. By 
employing a preformed complex of avidin bound to 
biotinylated peroxidase molecules, a sensitive 
avidin-biotin-peroxidase molecules, a sensitive 
avidin-biotin-peroxidase complex (ABC) system was 
developed. The complex is a lattice-like, three-dimensional 
formation which serves to localize several molecules of 
horseradish peroxidase at the site of antigen and can be 
demonstrated with a signal system such as hydrogen 
peroxide and diaminobezidine{DAB). The ABC procedure 
has been further refined by substituting avidin with 
streptavidin. Streptavidin has a neutral charge at 
physiological pH and does not produce the non-specific 
binding associated with egg-white avidin, which has a 
positive charge. Many commercial sources of ABC 
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reagents are currently available and they include kits such 
as the Super Sensitive kit (Biogenex ZPOOO-UM). 
Sequential overlaying of ABC-stained sections with an 
avidin-rich and biotin-rich complex, use of a streptavidin or 
avidin-horseradish peroxidase conjugate, and sequential 
application of the PAP and ABC techniques (ABPAP) have 
been described as methods to increase the sensitivity of 
immunostaining. The presence of endogenous biotin, 
which can bind the avidin peroxidase complex directly to 
produce non-specific or false-positive staining, is a 
potential problem with biotin-avidin staining procedures. 
This can be avoided by first incubating the specimen with 
free avidin followed by free biotin. 
3.) Heavy Metal Salts and Microwave-Stimulated Antigen 
Retrieval It has been suggested that heavy metal salts such as 
zinc can be potent protein precipitants forming insoluble 
complexes with polypeptides, so that the use of zinc formalin 
as a fixative may enhance immunostaining. There has also 
been a suggestion that post-fixation in zinc sulphate may 
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serve to improve immunostaining of previously fixed tissues. 
More recently, microwave heating of tissue sections in the 
presence of metal solutions has been shown to produce a 
dramatic recovery of many cellular antigens masked by 
cross-linking fixatives such as formaldehyde. Several 
antigen-unmasking solutions are now sold commercially. 
Some contain heavy metal solutions such asJead thiocyanate 
which are potentially toxic reagents. However, it has been 
found that citrate buffer produces, with few exceptions, 
increased intensity and extent of immunostaining of a wide 
range of tissue antigens. This is achieved by immersing 
deparaffinised and rehydrated sections in 10 mM citrate buffer 
at pH 6.2 and irradiating in a domestic microwave oven at 
maximum power setting until the solution boils. When boiling 
point is attained, the hot solution is discarded and replaced 
with a similar cool buffer solution and the process repeated. 
Alternatively, distilled water is added to replenish the volume 
of buffer before repeating the irradiation procedure. As soon 
as the solution boils, the irradiation is stopped and the 
sections allowed to cool in the heated solution for a further 20 
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mins before they are removed and subjected to 
immunostaining. 
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PATIENTS AND METHODS 
Patients and samples. All samples were from Hong Kong 
Chinese patients. Twenty-two samples of HCC were obtained 
which included 5 well-differentiated HCC (WD HCC), 6 well to 
moderately differentiated HCC (WD-MD HCC), or moderately 
differentiated HCC (MD-HCC), 4 moderately to poorly or poorly 
differentiated HCC (MD-PD or PD HCC), and 7 unspecified HCC 
or recurrent HCC (US HCC) respectively. Of these, 14 were 
related to chronic hepatitis B vims infection. As control tissues, 6 
samples of secondary liver tumors (metastatic adenocarcinoma 
from colon), 6 chronic hepatitis infected liver with cirrhosis, and 2 
samples from liver abscesses were used. Eighteen normal 
samples of liver tissues (from autopsy or transplanted liver) were 
also studied. The pathological characteristics and identification of 
HCC was performed by CT Liew, Associate Professor, Dept. of 
Anatomical and Cellular Pathology, CUHK. All lung samples 
were also from Hong Kong Chinese patients treated at the Prince 
of Wales Hospital. Thirty samples of lung cancer including 12 
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SCC, 10 ADC, 8 SCLC were also obtained. Normal lung tissues 
from 17 people who died from traffic accidents were kindly 
supplied by Dr. H.M. Wong, Kowloon Mortuary, Kowloon，Hong 
Kong. The diagnosis of the samples for lung cancer was 
performed by Dr. Louis Chow (Consultant Pathologist, PWH). 
Slide preparing. Tissue samples were obtained from resected 
tumors, livers, lungs and autopsy source. Cut tissue into small 
blocks, no more than 2cm square and 5mm thick. Then were 
immediately fixed in 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 24 hours. After tissue processing with 
dehydration through increasing concentrations of ethanol and 
cleaning tissue in xylene which were done by automatic tissue 
processing equipment. Infiltration of tissue with molten paraffin 
was done quickly to avoid prolonged exposure of tissue to 
elevated temperature and infiltration was best accomplished in a 
vacuum oven. (Avoid temperatures over 60°Cwhich may destroy 
protein and resulted in structurally damaged antigen) Tissue 
blocks sectioned on a rotary microtone about 3um-6um in 
thickness. Mounted from water onto silane coated microscope 
slides. Heat adhere sections at 55-60。C for several hours. 
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Adhesion of the section to the slide is essential to prevent tissue 
loss during subsequent incubations and washes. All steps were 
performed at room temperature (43). The detailed protocol of slide 
silanization is as following: 
1.) Wash slides in 2N HCL for 5 mins. 
2.) Rinse slides in distilled water for 1 mins. 
3.) Rinse in high-grade acetone for 1 min and air.dry. 
4.) Wash slides in 2% solution of organosilane in high-grade 
acetone for 1 min with gentle agitation. 
5.) Rinse slides in high-grade acetone for 1 min and air dry. 
6.) Store at room temperature in box for stock. 
(Organosilane : 3-Aminopropyltriethoxysilane, sigma : A3468, 
store at 0-5°C) 
lmmunohistochemical staining, lmmunohistochemical staining 
was analyzed with affinity-purified rabbit antibody raised against 
the recombinant PML protein as described previously {9-12). In 
brief, tissue samples were obtained from resected livers and 
tumors, and were immediately fixed in 4 % paraformaldehyde in 
phosphate-buffered saline (PBS) for 24 hr and embedded in 
paraffin. Tissue sections were prepared in silanization slides. 
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Also could direct use silane coated slides (sigma S4651, 
silane-prep slides) or polilysin coated slides (sigma P0425, 
poli-prep slides). All above steps were performed at room 
temperature. Slides were first heated at 60。C in an oven. After 
dewaxing with xylene, and rehydration with gradient alcohols, the 
slides were heated to boiling in 10 mM sodium citrate buffer pH 
6.8 for 10 min in a microwave oven. After treatment with 3% 
hydrogen peroxide in methanol to inactivate the endogenous 
peroxidase activity, the samples were blocked with the blocking 
solution which consisted of 5% bovine serum albumin (BSA) in 
PBS, for 20 min, and then with the first antibody, PML antibody 
(1:2,000 in blocking solution), for 1-2 h at room temperature. 
After washing 3-4 times with PBS, the samples were incubated 30 
min each with the secondary antibodies (goat anti-rabbit 
lgG-conjugated with biotin, and then with avidin-conjugated with 
horse radish peroxidase, BioGenex Lab., CA, USA), and washed 
with PBS after each step. The slides were developed with 
substrates for peroxidase (AEC or DAB reagents, Histostain kit, 
Zymed Lab, S. San Francisco, CA, USA), or with alkaline 
phosphatase (Double Labeling kit, Zymed Lab.). After 
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counterstaining with hematoxylin and briefly washing with 30 mM 
ammonium hydroxide, the slides were mounted with aqueous or 
permanent mounting medium. The expression of PML in the 
POD structure was rated as the following: ++++ and +++ very 
strong or >20 POD; ++ strong or 10-20 POD; + moderate or 5-10 
POD; +/- weak or partial, or 1-5 POD; and - negative. The detailed 
protocol of above procedure is as following: 
1) Deparaffinized tissue: 
Dip slide in Xylene for 5 mins 
second Xylene for 5 mins 
Third Xylene for 5 mins 
wash 2 X in 100% alcohol/5 mins each 
wash 2 X in 95% alcohol/3 mins each 
wash once in 75% alcohol/3 mins 
wash in distilled water for 1 min 
2) Soak slide in 10mM citrate buffer, pH 6.0, boil in microwave 
oven for 5 mins, add more buffer and boil for another 5 mins. 
3) Treat tissue with 3% H2O2 in methanol for 20 mins 
4) Add blocking solution (Super block from kit) and incubate at 
room temperature for 20 mins. 
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5) Add primary antibody (dilute in 1:5 dilution of super block in 
(PBS) at a predetermined dilution and period of incubation time 
(for PML antibody, use at least 3000 X dilution and incubate for 
2 hours). 
6) Rinse 5 times (4 mins each) in 1:10 dilution of super block in 
PBS. For the third wash, include 0.1% Tween-20 in buffer. 
7) Linking step: dilute 1:30 of the linking reagent in 1:5 dilution of 
super block in PBS, incubate at room temperature for 30 mins. 
8) Rinse as described in step 6. 
9) Labeling step: dilute label reagent 1:30 in 1:5 dilution of super 
blocks in PBS, incubate at room temperature for 30 mins. 
10) Rinse as described in step 6. 
11) Add chromogen/substrate (dilute chromogen 100 X in 1 X 
H2O2 substrate) and incubate at room temperature for 5-15 
mins until color development is complete. 
12) Counterstaining with hematoxylin and briefly washing with 
30mm ammonium medium. 
13) Mount and examine under microscope. 
For the proliferation marker Ki67, the deparaffinized and 
rehydrated slides were digested with 0.1 % trypsin in PBS for 10 
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min at room temperature. After washing with PBS, the samples 
were heated with microwave and processed as described. The 
mouse anti-human Ki67 antibody was a ready to used reagent 
from Zymed Lab.(No. 08-0156), and the incubation was at 1 hr at 
room temperature. The detail protocol of immunohistostaining for 
Ki67 antibody is as following: 
1) Deparaffinized slides as above described steps. 
2) Trypsin digestion: add 0.1% trypsin in PBS to slides, follow 
with 10 mins incubation at room temperature. 
3) Wash with PBS three times (3 mins each) 
4) Soak slides in 10mM citrate buffer (PH6.0) boil in microwave 
for 10 mins. (don't let slide dry) 
5) Treat tissues with 3% H2O2 in Methanol for 20 mins. 
6) Wash with PBS 
7) Proceed with ABC immunokit as above steps. Use primary 
antibody Ki67 (zy med, 08-0156, mouse anti-human Ki67 
antigen) to incubate about 60 mins. 
The antibody against the macrophage specific antigen KP1 was a 
mouse anti-human CD68, prediluted (Dako A/S, Denmark, No 
N1577). The slides were digested with 0.1 % trypsin for 10 min 
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at room temperature after deparaffinization and rehydration as 
described. After counterstaining with hematoxylin and briefly 
washing with 30 mM ammonium hydroxide, the slides were 
mounted with aqueous or permanent mounting medium. The 
detail protocol of immunohistostaining for KP1 is shown as 
following: 
1. Oeparaffin steps as above 
2. trypsin digestion: add 0.1 % trypsin in PBS following with 10 
mins of incubation. 
3. Wash with PBS three times (no need to perform the antigen 
retrieval using microwave for this antibody) 
4. Treat tissues with 30/0 H20 2 in Methanol for 20 mins of 
incubation. 
5. Wash with PBS 
6. Add blocking solution and incubate at room temperature for 20 
mins. Add primary antibody and follow with immunokit steps 
For Hela and Hela-PML cell staining by PML antibody. The Hela 
and Hela-PML cells could directly culture on glass slides or 
adhere to slides by cytospin method. The detail cytospin 
procedure is shown as following: 
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1) Make cell suspension about in concentration of 10^/ml. 
2) Add 3-4 drops of the cell suspension to slides and place slides 
in Shandon Cytospin II at 250 rpm for 5 mins. 
3) Remove slides individually from cytospin II and fix cytospins 
immediately in 4 % formaldehyde for 20 mins. Air dry and 
store -20。Cuntil ready for staining. 
4) Staining for PML antigen is similar to paraffin slides staining 
PML, but no need to perform antigen retrieval by microwave 
heating. Instead by soaking cytospin slides to 0.1% triton 
X-100 in PBS for 10 mins. After washing 3 times with PBS 
containing 0.1% BSA. Then followed with blocking step to start 
immunohistostaining kit staining procedure. 
On other hand, cells can culture directly on slides. This can keep 
cells in monolayer and completed morphology. First sterilized 
silanized slides by autoclave for 2 hours. Then put sterile slide on 
Petri dish and placing several drops of cell suspension with BSA 
for culturing overnight. When cells show confluent, harvest slides 
and wash with PBS for 3 times. Then fixing cells immediately 
using 4% formaldehyde for 20 mins and store -20°Cuntj| ready for 
staining. The staining procedure is as same as cytospin staining. 
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Cell culture. The human HeLa cell line was obtained from the 
American Type Culture Collection (ATCC), Rockville, MD. HeLa 
cells were transfected with the PML cDNA (HeLa-PML) and stable 
transfectants were obtained as described previously (22) (Dr. K.S. 
Chang, UT MD Anderson Cancer Center, Houston, TX USA). 
HeLa and HeLa-PML cells were grown as monolayer cultures in 
Dulbecco's modified Eagle's medium (DMEM) containing 10-13% 
heat inactivated fetal calfserum，2 mM L-glutamine, and 100-U/ml 
of penicillin and streptomycin, as described previously {6,11). 
HeLa-PML cells were incubated in the presence of the selection 
marker G-418 as described. Cell death assay was performed 
with the MTT assay. 
Determination of the population doubling times. Cell were 
plated at 5 x 10^ per well in a 12-well plate in triplicate and 
cultured in 1ml complete medium. The number of viable cells 
were determined by trypan blue exclusion assay and counted at 
daily intervals for 4 days. The detail trypan blue exclusion assay 
protocol as follows (44). 
1) Prepared cell suspension at a high concentration (〜105 cells/ml) 
by trypsinization or centrifugation and resuspension. 
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2) Take a clean hemocytometer slide and fix the coverslip in 
place. 
3) Add 1ml of cell suspension to one drop of 0.4% trypan blue in 
PBS on the open surface of the slide, mix, transfer to the edge 
of the coverslip, and allow to run into the counting chamber. 
4) Leave 1-2 min (do not leave too long or viable cells will 
deteriorate and take up stain). 
5) Place on microscope under ax10 objective. 
6) Count the number of stained cells and the total number of 
cells. 
7) Wash hemocytometer and return to box. 
8) Analysis. Calculate the percentage of unstained cells. This is 
the percentage viability by this method. If the volumes of cell 
suspension and stain are measured accurately at step 3，this 
method of viability determination can be incorporated into the 
hemocytometer cell counting protocol. 
The detail cell count protocol is as following: 
1) Prepare the hemocytometer slide: (a) Clean the surface of the 
slide with 70% alcohol taking care not to scratch the 
semi-silvered surface, (b) Clean the coverslip and, wetting the 
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edges very slightly, press it down over the grooves and 
semi-silvered counting area. The appearance of interference 
patterns ("Newton's rings" - rainbow colors between coverslip 
and slide like those formed by oil on water) indicates that the 
coverslip is properly attached, thereby determining the depth of 
the counting chamber. 
2) Trypsinize monolayer or collect sample from suspension 
culture. Approximately 10^ cells/ml minimum are required for 
this method so the suspension may need to be concentrated 
by centrifuging (100g for 2 min) and resuspending in a smaller 
volume. 
3) Mix the sample thoroughly and collect about 20 ul into the tip of 
a Pasteur pipette or micropipette. Do not let the fluid rise in a 
Pasteur pipette or cells will be lost in the upper part of the 
stem. 
4) Transfer the cell suspension immediately to the edge of the 
hemocytometer chamber and let the suspension run out of the 
pipette and be drawn under the coverslip by capillarity. Do not 
overfill or underfill the chamber or its dimensions may change 
due to surface tension; the fluid should run to the edges of the 
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grooves only. Reload the pipette and fill the second chamber if 
there is one. 
5) Blot off any surplus fluid (without drawing from under the 
coverslip) and transfer the slide to the microscope stage. 
6) Select x10 objective and focus on grid lines in chamber. If 
focusing is difficult because of poor contrast, close down the 
field iris or make the lighting slightly oblique by tilting the mirror 
or offsetting the condenser. 
7) Move the slide so that the field that you see is the central area 
of the grid and is the largest area that you can see bounded by 
three parallel lines. This area is 1mm. Using a standard 10 x 
objective, it will almost fill the field, or the corners will be slightly 
outside the field, depending on the field of view. 
8) Count the cells lying within this 1-mm area, using the 
subdivisions (also bounded by three parallel lines) and single 
grid lines as an aid to counting. Count cells which lie on the top 
and left-hand lines of each square but not those on the bottom 
or right-hand lines to avoid counting the same cell twice. For 
routine subculture, attempt to count between 100 and 300 cells 
per mm; the more cells that are counted, the more accurate the 
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count becomes. For more precise quantitative experiments, 
500-1,000 cells should be counted. 
9) If there are very few cells (< 100/mm), count one or more 
additional squares (each 1mm) surrounding the central square. 
10) If there are too many cells (> 1,000/mm), count only five small 
squares (each bounded by three parallel lines) across the 
diagonal of the larger (1-mm) square. 
11) If the slide has two chambers, move to the second chamber 
and do a second count. If not, rinse the slide and repeat the 
count with a fresh sample. 
12)Analysis. Calculate the average of the two counts, and derive 
the concentration of samples as follows: 
c = n/v 
where c = cell concentration (cells/ml), n = number of cells 
counted, and v = volume counted (ml). For the Improved 
Neubauer slide, the depth of the chamber is 0.1 mm, and 
assuming only the central 1 mm is used, v is 0.1 mm or 10 ml. 
The formula becomes: 
c = n x10. 
Hemocytometer counting is cheap and gives you the opportunity 
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to see what you are counting. If the cells are mixed previously 
with an equal volume of a viability stain, a viability determination 
may be performed at the same time. The procedure is，however, 
rather slow and prone to error both in the method of sampling and 
the size of samples and requires a minimum of 10^ cells/ml. Most 
of the errors occur by incorrect sampling and transfer of cells to 
the chamber. Make sure the cell suspension is properly mixed 
before taking a sample. And do not allow the cells time to settle or 
adhere in the tip of the pipette before transferring to the chamber. 
Ensure also that you have a single cell suspension as aggregates 
make counting inaccurate. Larger aggregates may enter the 
chamber more slowly or not at all. 
MTT Assay. For measurement of cytotoxicity and viability, the 
choice of assay will depend on the agent under study, the nature 
of the response and the particular target cell. The MTT 
(tetiazolium) assay was use to determine the growth-inbibitory 
effects of different drugs. It was innovated in microtitration assay. 
It has been the use of reduction of tetrazolium to a coloured 
formazen as an indicator of viability. A 5mg/ml solution of MTT 
[3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazoliunn bromide; 
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sigma, M5635] was prepared in complete medium, filtered (0.22 
um) sterilized, and them store at 4。C. The detail microtitration for 
cisplatin and MTT assay protocol show as following: 
1. Trypsizine cells, seed microtitration on 96-well plates at 5 x10^ 
cells/well, 0.1ml/well, set up one duplicate plate for cell 
counting. 
2. Place plate in CO2 incubator with loose-fitting lid for overnight to 
equilibrate with CO2. 
3. Prepare drug difference dilutions (cisplatin.) in complete 
medium, cis-platin was added in volume of 5ul to to get final 
concentration of cisplatin in 0，1，5，10//g/ml. (21wells each). 
4. Incubate a further two nights. Add MTT solution 10ul/well in 
concentration of 5ug/ml in complete medium, incubate at 
standard condition for more 4 hours. 
5. Remove medium (containing cisplatin and MTT) from well. Add 
lysing buffer DMSO 100ul per well, shaking well for several 
hours. 
6. Plate read on an automatic plate reader (Biotech) at 570nm. 
7. Analysis and calculate LD50. 
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RESULTS 
Altered expression of PML in normal liver, HCC and 
secondary liver tumors. To determine the expression of PML 
in normal liver，liver biopsy samples were obtained and analyzed. 
As shown in Figure 1A, low but detectable levels of PML were 
found in the nuclei of hepatocytes as POD or nuclear bodies 
structure in 18 samples analyzed (14 +/- and 4-) confirming 
results previously published by others (27-29). Other cells that 
are known to express low levels of PML in liver included the 
Kuppfer cells, activated macrophages, epithelia and endothelial 
cells (27-29). When HCC samples were analyzed for PML 
expression in the POD, 5-10 fold increases in expression of PML 
were found in the tumor cells. In addition, endothelial cells, 
epithelia, activated macrophages, lymphoid cells and Kuppfer 
cells were also highly induced and stained positive for PML As 
shown in Figure 1B, considerable enhanced expression of PML in 
the nucleus was found in a large numbers of HCC samples. The 
typical trabecular arrangement with endothelial-lined sinusoids 
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separating the aggregates of tumor cells were also observed. 
Interestingly, in some samples of HCC, a cytoplasmic localization 
of PML was observed. To determine if the enhanced expression 
is specific to primary liver neoplasia, several samples of 
secondary liver cancers were investigated. As shown in Figure 
1C, the expression of PML in secondary liver cancers, which were 
colon adenocarcinomas that metastasized to the liver, was usually 
ranging from moderate to low but still detectable. However, the 
staining was mostly confined to the nucleus as nuclear bodies or 
POD structure. In contrast, the liver cells surrounding the cancer 
contained increased levels of PML both in the nucleus and in the 
cytoplasm. In addition, the expression of PML was also found to 
increase in the infiltrating lymphocytes, macrophages and 
fibroblast cells. 
Increased expression of PML in chronic hepatitis tissues. 
Although the precise relationship between hepatitis and liver 
cirrhosis and HCC is still uncertain, it is believed that chronic 
hepatitis and cirrhosis are premalignant lesions. To determine if 
the increased expression of PML is also associated with 
precancerous conditions of HCC, cirrhotic liver samples of 
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patients with chronic hepatitis were immuno-stained with PML as 
described. As shown in Figure 2A, strong nuclear staining of 
PML were found in the hepatocytes of the hepatitis tissues similar 
to the non-tumor area of HCC slides which were usually cirrhotic 
in nature. However, cytoplasmic localization of PML was also 
observed in hepatitis tissues. In addition, the infiltrating 
lymphocytes and macrophages surrounding the cirrhotic liver also 
showed strong expression of PML which indicates that the 
enhanced expression of PML is occurring in multiple cell types. 
The staining was mostly homogeneous, uniformly distributed and 
with a diffuse pattern. The surrounding Kupffer cells, which are 
one of the sinusoidal endothelial cells and the resident 
macrophages in the liver, were also stained strongly by the 
antibody against PML Kupffer cells take important roles in the 
biological defense mechanism and in the maintenance of 
homeostasis of the body. As shown in Figure 2B, strong PML 
staining was observed in lymphocytes surrounding the cirrhotic 
liver nodules. In addition, the expression of PML in bile duct 
epithelial cells of hepatitis tissues, was found to increase 
significantly comparing to the control liver. As shown in Figure 
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2C, the epithelial cells associated with the bile duct were strongly 
stained by the antibody against PML, indicating that the 
enhanced expression is present in several cell types. To 
determine if the enhanced PML expression is also associated 
with other pathologic condition of the liver, liver abscess was 
analyzed. Interestingly，in samples of abscess, increased 
expression of PML was also observed in certain cells. As shown 
in Figure 2D，the layer of cells surrounding the abscess contained 
increased levels of PML as compared to the neighboring cells. 
These results strongly indicated that enhanced PML expression is 
associated with the process of inflammation and/or cell death, 
most likely with the compensatory cell growth during cell injury. 
The results for the various subtypes of HCC and secondary liver 
cancers were tabulated as shown in Table 1A. The number of 
HCC analyzed and the levels of expression of PML is shown. 
Five cases of WD HCC contained mostly moderate (+) to weak 
(+/-) PML expression at tumor-center, while strong (++) to 
moderate (+) PML were found in peri-tumor region. The 
surrounding non-tumor tissues which were mostly cirrhotic 
expressed high PML (+++ to +). Similar results were found with 
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the WD-MD HCC and MD HCC. For the MD-PD HCC and PD 
HCC, and the US HCC (unspecified), slightly more intense 
staining of PML were observed. Most of the tumor cells at the 
peri-tumor regions showed strong {++) or moderate (+) PML 
expression. The majority of secondary liver cancer from colon 
metastasis only showed moderate expression (4 out of 6 were +) 
in both tumor center and at peri-tumor regions. In contrast, the 
surrounding non-tumor regions of most liver cancers showed very 
strong (1+++, 4++ and 1+) expression of PML Similarly with 6 
liver of chronic hepatitis with cirrhosis, 2 samples were +++ while 
4 samples showed ++ expression. In contrast, the 18 normal 
liver all showed weak/partial or negative expression (14 +/- and 
4-). These data indicate that increased PML expression is 
associated with liver cirrhosis and HCC. Since the 
non-tumorigenic regions of the HCC samples were mostly 
cirrhotic in nature, it is not surprising that the expression of PML 
was also strong. However, the expression of PML appears to 
have no direct correlation with the differentiation phenotypes of 
HCC, although an inverse correlation were found in US HCC and 
the PML expression at the center of tumors (only 2 out of 7 
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samples showed positivity). 
Differential expression of PML at the periphery and at the 
center of single-encapsulated lesion of HCC. It was not 
known why certain HCC tumors expressed high levels of PML 
while in others the expressions were low. To determine if there is 
a difference in the expression of PML in the peri-tumoral regions 
and at the center of the tumor, HCCs with large and single 
encapsulated lesions were then analyzed for the expression of 
PML In Figure 3，a region between the periphery and the tumor 
center of a HCC is shown. The PML staining pattern appears to 
have a gradation of intensity ranging from strong at region close 
to the peri-tumor to weaker expression towards the center of 
tumor. As shown in Figure 4 in higher magnification, enhanced 
expression of PML was found in the neoplastic cells at the 
periphery of the HCC (Panel A), which is apparently the site of 
rapid proliferation and expansion. The surrounding 
encapsulated fibrous layers of connective tissue stroma 
contained numerous fibroblasts and lymphocytes that 
over-expressed PML (data not shown). However, the 
expression of PML was progressively decreased to moderate or 
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very low levels at the center of the tumor (Panel B). In contrast, 
PML expression in HCCs with multi-encapsulated lesions or with 
numerous fibrosis encapsulations was usually high and did not 
show a gradient of diminishing expression. Interestingly，a 
differential expression of PML was found in single- versus 
multi-encapsulated region of HCC as shown in Table 1B. A 
large number of single-encapsulated lesions of HCC (8 out of 14 
or 57 %) showed decreased or no expression of PML at the 
tumor center. In HCC with multiple encapsulated lesions, only 2 
out of 9 (22%) showed negative PML expression, while the 
majority (78%) showed positive or enhanced PML expression. 
These results, taken together, indicate that PML expression in 
liver and in HCC is rather complex, and it is apparently 
associated with mediators in the microenvironment of the 
peri-tumor region. 
Expression of PML in Normal Lung tissues. To determine if 
altered expression of PML was also present in lung cancer, which 
is one of the major cancer in Asia. As shown in Figure 5 Panel 
A, normal tissues of human lung contained moderate to 
moderately strong expression of PML protein in the nucleus as 
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speckled or defused POD structure in fibroblasts, pneumocytes, 
macrophages and endothelial cells indicating PML expression is 
apparently essential for the function of various cell types in lung. 
In a total of 17 samples analyzed 1 was +++, 13 were with ++ and 
3 were + for PML expression fTable 2). To determine if PML 
expression was altered in lung neoplasias, several histological 
types of human lung cancers were investigated. 
Suppression of PML Expression in Small Cell Lung Cancer. 
Samples of SCLC were first obtained and analyzed for PML 
expression (Figure 5, Panel B, C, D). Unlike the normal lung 
tissues, the levels of PML staining in 8 samples of SCLC 
examined were either very low or undetectable (6- and 2+/- both 
in the central and in the peripheral regions as shown in Table 2). 
In contrast, the adjacent non-tumor cells stained strongly or 
moderately strong for PML (1+++, 4++ and 1+). 
Enhanced Expression of PML in Adenocarcinoma of the 
Lung To determine if PML expression is also altered in ADC of 
the lung, 10 samples of ADC were analyzed. Increased 
expression of PML was found in almost all of the ADC analyzed 
(Figure 6A, 6C). The expression of PML was ranged from very 
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strong to moderate (1++++, 6+++ and 3++) in the peripheral 
region of the tumors. However, decreased PML expression was 
observed at the central region of the tumors which ranged from 
1++，5+ to 5+/- 0"able 2). The non-tumor cells at the peripheral 
regions contained strong and moderately strong expression of 
PML (7+++ and 5++). 
Enhanced Expression of PML in Squamous Cell Carcinoma 
of the Lung 
When SCC of the lung tissue was examined, a similar pattern to 
that of ADC was observed. As shown in Figure 6B, 6D, the 
expression of PML in primary SCC lung cancers was usually 
ranged from strong to very strong. However, the staining were 
mostly confined to the nucleus as nuclear bodies or POD 
structure. In contrast, the epithelial cells, fibroblasts surrounding 
the cancer contained increased levels of PML Most interestingly, 
PML was expressed most strongly for the cancer cells at the 
periphery of the tumors as well as in the surrounding non-tumor 
cells. PML expression progressively decreased to almost 
undetectable levels at the central region of the tumors. In 12 
samples of SCC examined, the staining pattern for the tumor cells 
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at the central region of the tumor were 6+，3+/- and 3-，while that 
for the tumor cells at peripheral regions were 4++++ and 8+++. 
The non-tumor cells at the periphery were 7+++ and 5 ++ fTable 
2). 
Expression of PML in Metastasis of Lung Cancer Metastasis 
samples of lung cancer were also prepared and reacted with 
antibody against PML. As shown in Figure 7A, a metastatic 
tumor of SCC of the lung infiltrated a blood vessel contained 
considerable expression of PML Similarly, in metastatic tumors 
of SCC that involved regional lymph nodes, enhanced expression 
of PML was also found (Figure 7B). The staining was ranged 
from +++ to ++• In a total of 6 metastases analyzed, 2 with +++ 
and 4 with ++ were found. There was no difference of PML 
expression observed between tumor center and peripheral 
regions，and the non-tumor cells at the peripheral region also 
expressed considerable amount of PML 
Inverse Correlation of the Expression of PML and the 
Proliferation Marker Ki-67 in SCLC and SCC To determine if 
enhanced PML expression was associated with cells that are 
rapidly proliferating, single- and double-labeling were performed 
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on samples with antibodies against PML and the proliferation 
marker Ki-67. As shown in the color print of Figure 8 Panel A, 
the staining of PML in the cluster of blue staining tumor cells in 
SCLC was undetectable (thick arrow while the expression of PML 
(brownish-red staining) in the adjacent non-tumor region was 
mostly positive (thin arrow). In Figure 8 Panel B, double staining 
of the same SCLC sample, showed that the cluster of tumor cells 
(thick arrow) which contained Ki-67 positive cells (dark brown 
staining of DAB) did not express PML (red staining of AEC), while 
the neighboring non-tumor cells (thin arrow) which expressed 
PML were devoid of Ki-67. For SCC samples (Figure 8，Panel 
C), double labeling showed that the majority of tumor cells that 
expressed strong levels of PML was devoid of Ki-67 staining (thin 
arrow) indicating that PML expression was inversely correlated 
with Ki-67 expression in these tissues. A minor proportion of the 
tumor cells in SCC was found to stain positive with Ki-67 (thick 
arrow). 
Correlation of the expression of PML in macrophages with 
the macrophage-specific marker KP-1 To determine if 
macrophages express PML, double staining technique was 
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performed with PML and the macrophage specific marker KP-1 
on the same slides. As shown in Panel D-F of Figure 8，most of 
the macrophages were stained positive with KP-1 (DAB stain 
which stained the cytoplasm of macrophages in dark brown). In 
non-tumorigenic lung tissues with inflammation as shown in 
Figure 8，Panel D, many of the macrophages were stained 
positive for both KP-1 and PML indicating that the macrophages 
expressed enhanced levels of PML (red nuclear staining of AEC 
chromogen), an indication of the presence of activated 
macrophages. In contrast, many of the macrophages 
associated with the lung cancer (50-60 %) did not express PML 
as shown in Figure 8，Panel E. The cells stained positive with 
the macrophage marker KP-1 (cytoplasmic staining of dark brown 
color) were devoid of PML expression with a clear nucleus as 
indicated by the thick arrow. For comparison, the tumor cells 
were stained positive with PML as indicated by the thin arrow. 
Similarly, in giant cells which are fusion of macrophages, the 
staining of PML was mostly negative (Figure 8 Panel F). 
Expression of PML in HeLa cells and HeLa cells transfected 
with the PML gene. To further elucidate the function of the 
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suppressor PML, HeLa cells and HeLa cells transfected with the 
PML gene was analyzed. These cells were first analyzed for the 
expression of PML protein. As shown in Figure 9， 
lmmunohistochemical staining of PML showed that HeLa cells 
contained a limited amount (2-6) of PML associated POD 
structure and low levels of PML expression (Panel C). In 
contrast, the HeLa-PML cells contained increased levels (5-10 
fold) of PML staining as compared to the control (Panel D). 
Many of the PML staining appeared as homogeneously staining 
regions at the nucleus. 
Altered morphology of the HeLa-PML cell-clones. In addition, 
we have observed that the HeLa-PML cells formed cluster of cell 
clones which was different from the parental HeLa cells. As 
shown in Figure 10, Panel A is the parental HeLa cells which 
formed monolayer of single cells. In contrast, the HeLa-PML in 
Panel B formed clusters of cell colony in the cell culture. 
Furthermore, the Hela-PML cells became easily detached from 
the culture flask when treated with 0.25% trypsin in PBS. 
Altered growth rate in Hela-PML cells. To test the effect of 
increased expression of PML on cell growth in Hela cells, the 
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growth characteristics of Hela and Hela-PML were determined as 
described in methods by determinations of the population 
doubling times. Results as shown in Figure 11 indicate that PML 
transfected clones had a significantly slower growth rate 
compared to the parental Hela cells. This results indicate that 
increased expression of PML in Hela cells leads to a reduced cell 
growth rate. 
Altered rate of cell-death in HeLa-PML cells. To elucidate if 
PML may affect the cellular response to DNA damages, HeLa 
and HeLa-PML cells were treated with an anti-cancer agent, 
cisplatin. As shown in Figure 12，increased cell death was found 
in HeLa-PML cells as compared with the parental HeLa cells. At 1 
and 5 ^g/ml of Cisplatin, the survival fractions were 30% and 10% 
respectively for the HeLa-PML cells while the fraction for HeLa 
cells were at 60% and 30% respectively. These data indicated 
that the presence of additional copies of PML gene rendered the 
HeLa-PML cells to be more sensitive to drug-induced cell death. 
50 
DISCUSSION 
Cancer developments including that of liver and lung cancers 
appear to be multistage-multihit processes in which normal cells 
progress to malignant neoplasia through an accumulation of 
genetic and epigenetic changes (11-14). Many of these genomic 
and phenotypic alterations reside in proto-oncogenes and 
oncosuppressor genes which are known to affect cellular 
proliferation and signal transductions (11-13). In addition, there is 
considerable evidence supporting the importance of 
oncosuppressor genes in regulating cell growth and differentiation. 
Some of the oncosuppressor genes are also responsible for 
protecting cells from the deleterious effects of DNA damage and 
xenobiotics by arresting cell cycle progression and by triggering 
programmed cell death (11-15). The p53 gene is a prototype 
example in which mutated forms of the gene had been found in 
many tumor types (14). Over-expressions of the p53 as a result of 
increased stability of the protein were found in cancer cells that 
either contained the mutated gene, or when the p53 protein was 
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sequestered and inactivated by viral proteins. On the other hand, 
mutations in specific regions of the gene may contribute to the 
aberrant localization of the gene product (11-15). Since not all 
tumors contain defective p53, it is believed that other molecules 
that regulate cell growth and differentiation may be involved in the 
loss of growth control during oncogenesis. PML has been found to 
accumulate at the border of a nuclear structure, namely the 
nuclear bodies or the PML Oncogenic Domain (POD)(28,33). 
PML co-localized with several proteins including the Sp-100, 
NDP55, PIC 1，lnt-6 and possibly others in the POD structure 
(30-33). Evidence had been documented that PML may play a 
role in viral replication (34-37). Whether the HBV contains a gene 
the product of which may interact with PML is at present unknown. 
Moreover, the specific target genes for PML are also not known, 
the gene products that co-localized with PML in the POD structure 
may represent some of the target genes of PML or that these 
proteins may regulate PML However, the precise function of PML 
and the POD structure is also unclear. One hypothesis put forth 
by Maul and co-workers (33) is that the nuclear bodies or POD 
may represent storage sites of certain matrix proteins readily 
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accessible throughout the chromatin in response to stress or other 
effectors that induce global nuclear changes. Thus, PML may act 
as a matchmaker to recruit or sequester other proteins in or out of 
the POD. Nevertheless, PML may play an important role in the 
loss of growth control and in the oncogenesis of many cancers. 
The gradient of expression of PML found in HCC is somewhat 
unexpected but is not surprising. Many regulatory molecules show 
a gradient of expressions in tissues, cells and embryos. PML 
expression in HCC is probably analogous to the oxygen gradient 
in tumors in which the tumor centers are mostly hypoxic while the 
peri-tumor regions are oxygen-rich because of the availability of 
ample blood supplies. Although the exact reason for the gradient 
of PML expression is not known, it could be an indication that 
cells at the peri-tumor regions and those at tumor-centers belongs 
to different stages of the tumorigenic process. In addition, 
cytokines and lymphokines are known to be produced by cells in 
the inflammatory regions, and since PML expression can be 
induced by cytokines i.e. interferons, PML was being activated in 
both the tumor and non-tumor cells at the peri-tumor regions. 
Thus, the alternative explanation is that the gradient of expression 
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of PML in tumors is a reflection of the differential concentration of 
the secreted cytokine(s) at different regions of the tumors. 
Our data on the enhanced nuclear and cytoplasmic expression of 
PML in HCC and hepatitis with an antibody raised against the 
recombinant protein, are in general agreement with those 
published previously (27-29) indicating that the PML displays an 
altered expression pattern during human oncogenesis. The 
results previously reported include using a polyclonal antibody 
raised against the recombinant PML protein and the 5E10 
monoclonal antibody which was previously shown to recognize 
nuclear matrix-associated nuclear bodies. We have also 
confirmed the published results of Terris and co-workers (28) that 
PML expression is enhanced in several cell types of the 
inflammatory tissues in liver because chronic inflammation and 
cell injury induce signals for apoptosis and regeneration, which 
affect cell cycle progression, and the expression of PML 
Inflammatory cells may increase the secretion of growth factors, 
cytokines and hormones. These biological mediators may in turn 
induce the expression of cellular stress responsive genes and 
growth regulatory genes including PML in neighboring 
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hepatocytes. In addition, we have observed 50-60 % of HCC 
over-express PML which is similar to that of Terris et al. (28), of 
78% (18/23) PML-positivity. However, heterogeneous nuclear 
expression of PML protein was also reported in normal and 
neoplastic tissues (27). Carcinomas of the larynx and skin were 
reported to express low levels of PML while the expression of 
PML in oat cell carcinomas of the lung were reported to be high. 
The mechanism for the differential expression of PML in various 
types of tumors is at present unknown. Although some of these 
can be attributed to tissue specific expression, our data showing 
the differential expression of PML at various sites of a single 
encapsulated lesion of HCC perhaps could resolve some of the 
apparent discrepancy and raise a cautionary note for the analysis 
of partial specimens. In contrast, multi-encapsulated lesions of 
HCC or tumors with numerous encapsulation and peri-tumoral 
fibrosis usually express high levels of PML, and did not show a 
gradient of decrease expression. Apparently cells at the 
periphery are rapidly dividing which express high levels of PML, 
while cells at the center of the tumors, which has limited blood 
supply, are usually proliferating at a slower rate and are starting to 
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go through the process of programmed cell death. Another 
possibility is that cells at the center may have different 
transformed phenotypes as compared to those at the peri-tumor 
regions. It was reported previously that epithelial tumors showed a 
gradual increase of PML levels as the lesion progresses from 
dysplasia to carcinoma, but when malignant cells turn invasive, 
they loose PML expression (27). 
There are apparently at least two mechanisms for the induction of 
PML expression, namely transcriptional regulation and 
post-transcriptional modification. The enhanced mRNA levels of 
PML after interferon induction as reported previously (23,30) 
belongs to the first kind, and the accumulation of PML transcripts 
is apparently a primary response to interferon, since it was 
reported that de novo protein synthesis is not required. On the 
other hand, enhanced PML expression after treating cells with 
ionizing radiation is a post-transcriptional modification event since 
ionizing radiation arrests cells in G1, and does not involve the 
alteration of the mRNA level of PML (Chan et al. unpublished 
data). The mechanism for the over-expression of PML in HCC 
and chronic hepatitis may involve either one or both of these two 
56 
possibilities. Thus, the altered expression and localization of PML 
could be the consequence of the PML protein being modified or 
sequestered by viral or cellular proteins including 
post-transc_onal modifications such as phosphorylation or 
dephosphorylation. Moreover, the enhanced expression of PML in 
these cells could be an intrinsic property of the cell types, or it 
could be an inducible expression as a consequence of the 
increase secretion of biological response modifiers. PML is known 
to be inducible by cytokines such as interferons and estrogen, 
which are produced in response to stress and inflammation. 
Increased expression of PML was found in cells induced to 
monocyte activation or differentiation. Our data on the differential 
expression of PML in the periphery and at the center of HCC 
supports the notion that the enhanced PML is a reflection of the 
inducible levels. Judging from the fact that the expression of PML 
was strongest in the inflammatory regions of the liver, which were 
known to be associated with the infiltration by macrophages and 
lymphoid cells. It is highly likely that the PML levels in hepatocytes 
were influenced by cytokines released from the lymphoid cells. 
Since there is an association between liver cirrhosis in 70-90% of 
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oriental patients with HCC, liver cirrhosis and chronic 
inflammation are believed to play an important role in promoting 
the development of HCC. Chronic inflammation and cell injury 
may increase the secretion of growth factors, cytokines and 
hormones, which in turn induce the expression of cellular genes in 
hepatocytes. In this context, PML is apparently playing a key role 
in transducing the proliferative stimuli for liver regeneration, which 
also could act as promoters for carcinogenesis in pre-initiated 
hepatocytes. 
In this report PML expression in SCLC was found to be either very 
low or undetectable in all of the 8 samples examined. The result 
is in accordance with those of a previous report by Gambacorta et 
al. (29). In contrast, we found considerable expression of PML in 
ADC, SCC and in lung metastasis which suggested that PML may 
play an important role in the oncogenesis of SCLC. SCLC, 
which constitutes 25 % of all lung cancers, is a highly aggressive 
tumor that disseminates early. For this reason, s _ c a l resection 
can seldom be performed, and thus the prognosis is often very 
poor (7-10). In addition, SCLC is a distinct histological, clinical, 
biochemical and biological type of lung cancer that is strongly 
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linked to cigarette consumption. Since SCLC expresses a wide 
range of neuro-endocrine peptides, and bioenergetic enzymes, it 
has been suggested that SCLC may arise from rare clusters of 
neuro-endocrine producing cells which are located beneath the 
bronchial mucosa. However, conflicting histological lineages 
have been reported based on surface markers, and the cell of 
origin for SCLC and NSCLC has not been defined clearly (7-9). 
Moreover, evidence for phenotypic plasticity in lung cancer cells 
has been documented, and considerable evidence suggests that 
the four major types of human lung cancers are all derived from 
normal bronchial epithelial cells (8). 
The report by Koken and co-workers analyzing various types of 
breast and colon neoplasms indicated (20) that PML expression 
gradually increase from benign dysplasia to carcinoma, and when 
malignant cells turn invasive, they loose PML expression. On 
the other hand, Gambacorta et al (22) subsequently documented 
that they did not observe this specific change of PML expression 
in analyzing a variety of tumors. The reason for these divergent 
findings is currently unknown, but it could be due to the use of 
different antibodies and reagents. Gambacorta and co-workers 
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(29) indicated that they used an antibody PG-M3，the epitope of 
which is partially resistant to fixatives and only cells that 
over-express PML are detected. Our findings of differential 
expression of PML in different types of cancers, and the 
observation that there is a gradient of PML expression in SCC 
and ADC might, in part, resolve this discrepancy. This gradient 
of PML expression is possibly related to the degree of malignancy 
or to the transformed phenotypes of the cells at various locations 
of the tumor. Alternatively, this may be the result of the levels of 
cytokines and hormones in the microenvironment of the tumor. 
The levels of PML could reflect the induced expression by the 
varying levels of biological mediators in the region. 
This is also the first report to use double staining of PML and 
KP-1 to identify macrophages that express PML and that giant 
cells of fused macrophages were negative for PML expression. 
Our finding of tumor macrophages expressing low levels of PML 
while those of normal or non-tumorigenic specimens did not is 
also noteworthy. Enhanced PML expression may be unique for 
a subset of activated macrophages, and thus, it could play an 
important role in the various stages of macrophage activation. 
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On the other hand, the double labeling experiments with PML and 
Ki-67 in SCLC indicated that the SCLC cells, which are apparently 
active in cell growth and therefore stained positive with the 
proliferative marker Ki-67, showed negative staining for PML 
However, the neighboring non-tumor cells, which were 
non-proliferative and stained negative for Ki-67, showed strong 
PML expression. These results support the notion that PML is a 
growth and transformation suppressor, and that it may play a 
crudal role in the loss of growth control of SCLC. 
In contrast, increased PML expression was found in most of the 
tumor cells of the peripheral regions of SCC and ADC, which 
include the invasive tongues of the tumors. This finding is 
apparently similar to those observed by us previously in HCC (41) 
and the expression of PML is apparently tumor specific. Unlike 
HCC or hepatitis tissues, cytoplasmic localization of PML was not 
observed in all of the lung cancers examined. Whether the 
differential expression of PML protein is a reflection of the number 
of cells arrested in G1 or that it is a response to signals of stress 
and inflammation associated with tumor growth remains to be 
investigated. The other possibilities including altered stability of 
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the PML protein, as it is being modified or sequestered by cellular 
proteins and altered transcription also can not be ruled out. 
The results of HeLa cells transfected with the PML genes showed 
increased PML protein expression are in accordance with the 
previously published data. In addition we found that the 
HeLa-PML cells formed clusters of cell-colony which differed from 
the control cells. The reason for this is currently unknown. 
However, the expression of proteins in the cell membrane 
including adhesion molecules may be altered in HeLa-PML, which 
may account for the growth-arrest induced by PML The data of 
HeLa-PML being more sensitive to cisplatin-induced cell death is 
also consistent with published data of PML being essential for 
multiple apoptotic pathways (38,39). 
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Further study 
This study demonstrated that PML expression was almost 
completely absent in all of the small cell lung cancer (SCLC) 
samples examined, while enhanced expression was found in 
adenocarcinoma and squamous cell carcinomas of the lung, and 
moderate expression was found in normal lung. The specific 
inactivation of PML may be an obligatory step in the 
tumorigenesis of SCLC. To further identify the roles of PML in 
control of cell growth and the possible mechanism of its effect in 
SCLC, the further study had been proposed as following: 
(1) confirm if the expression of the PML protein is suppressed in a 
larger cohort of SCLC tissues and cell lines ； 
(2) determine if the levels of mRNA and the structure of the PML 
gene are altered in SCLC ； 
(3) Transfect the wild-type PML cDNA into SCLC cells in order to 
determine if this suppressor would specifically inhibit cell 
growth and the transformed phenotypes of SCLC. 
63 
The detail further research plan already had been designed as 
following: 
1. Analysis of altered PML expression in SCLC and NSCLC. In 
the first phase, we shall further determine the expression of 
PML by immunohistochemistry in a larger number of SCLC 
and NSCLC samples. Other control tissue samples including 
normal tissues from lung, emphysema, pulmonary tuberculosis 
as well as lung abscess will also be analyzed. Samples will be 
obtained from the archival files of the histopathology section of 
the Prince of Wales Hospital, CUHK, or supplied as freshly 
resected specimens and from needle lung biopsy. One half of 
the samples will be fixed in 4% paraformaldehyde for use as 
paraffin embedded blocks, and the other half of the samples 
will be quick-frozen in an ethanol/dry ice bath and stored at 
-80。Cfor subsequent isolation of RNA and DNA. The samples 
will be classified and graded histologically by Dr. Louis Chow, 
a Consultant Pulmonary-Pathologist from PWH. Depending on 
the availability of the tissues, 20-50 samples of each category 
will be analyzed. The number of POD or nuclear bodies per 
nucleus will be counted and the intensity of the nuclear bodies 
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will be quantitated by comparison with the control normal lung 
and to the positive control cells (fibroblast HSF23). We have 
obtained preliminary results indicating that the expression of 
PML in normal lung is moderately strong (see Appendix). The 
intensity of the staining will be graded as strong positivity 
(+++), moderate positivity (++), weak positivity (+), 
negativity/weak positivity (-/+) and negativity (-). The statistical 
significance of the results will be determined by the student 
t-test. In addition, the diffused and microgranular or speckled 
pattern of PML, as well as the cytoplasmic localization of POD 
will also be determined. 
2. Analysis of PML mRNA in SCLC. After establishing the 
characteristics of the PML expressions as measured by 
immunohistochemical staining, we shall then determine if the 
levels of PML mRNA using ln-Situ hybridization of RNA or by 
Northern blotting of RT-PCR products. Since PML is known to 
be associated with several nuclear proteins including Sp-100, 
NDP-55, PIC-1, and lnt-6, in the POD structure, and since 
immunohistochemical staining only reveal the accessibility of 
the PML epitope in the giant-structure of POD, it is still not 
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known if the levels of PML, protein and RNA are also 
suppressed in SCLC. The results of ln-Situ hybridization of 
RNA on tissue slides and the RNA blotting will be correlated 
with the levels of POD or the diffuse pattern of PML. Since the 
samples of SCLC received are usually from needle biopsy and 
are usually small, the ln-Situ hybridization to RNA on slides 
will be performed first. Although Western blotting may reveal 
the amount of PML proteins in SCLC, the method has so far 
proved unsuccessful in our laboratory. This is probably due to 
the instability of PML after dissociation of the protein from the 
POD structure. Only samples with known histology wiil be 
analyzed by these procedures and the ratio of tumor cells will 
be quantitated for each specimen before analysis. If the levels 
of PML mRNA correlate with the PML in POD structure, the 
regulation of PML is apparently at the transcriptional level. On 
the other hand if the levels of PML mRNA are similar in both 
neoplastic and normal tissues, the altered PML as seen in the 
POD structure could be interpreted as being the result of 
post-transcriptional modification such as decrease in protein 
stability, sequestration by other proteins, altered 
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phosphorylation and/or altered conformation of the PML 
protein. Simultaneously, we shall determine in cell lines of 
SCLC if the expression of PML may also be suppressed. 
3. Analysis of the structural alterations of the PML gene in SCLC. 
After the analysis of protein and mRNA of PML, the second 
phase aims to determine if deletion or mutations in the PML 
gene may account for the aberrant expression of the PML 
protein. It is known that certain mutant forms of tumor 
suppressor genes may be more susceptible to degradation 
while other mutant forms with frame shift mutation or 
truncation do not express proteins. To accomplish this, mRNA 
will be purified from 4-6 samples of SCLC tumor and cell lines 
and from normal tissues using the TRIzol reagent kit from Life 
Technology Inc., and the PML cDNA wi" be synthesized by 
RT-PCR. The PML cDNA will be hybridized to RNA 
synthesized from a plasmid with the wild-type PML gene. The 
heteroduplex formed will be subjected to RNAase A digestion 
using a Mismatch Detect II Kit from Ambion Inc. Austin TX. 
Mismatches formed as a result of mutations present in the 
cDNA of the tumor samples will be cleaved by the RNAase. 
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This is a sensitive and reliable technique in screening 
unknown mutations and/or deletions present in a gene, and a 
kit is currently available from commercial source (Ambion 
Biotech. lnc.).The mutations found will subsequently be 
confirmed by direct DNA sequencing method. If the level of 
PML mRNA was decreased and there is no mutation found in 
the gene, the likely explanation is transcriptional suppression. 
Hyper-methylation of the regulatory CpG sequence of the PML 
gene, similar to those of the suppressor gene p16, or by 
altered regulatory factor(s) for transcription is the possibilities. 
On the other hand, if there are no changes in mRNA and DNA, 
the decreased PML protein could be the result of modulation 
by proteins associated with the preneoplastic and/or 
tumorigenic cells. Decreased PML expression in these cells 
may then provide a growth advantage for the development of 
the neoplasia. Thus, the elucidation of the role of this 
important growth suppressor will have great ramification for 
the etiology and management of SCLC. 
4. Transfection of the wild-type PML cDNA into SCLC cell lines. 
The third phase of the program will be to determine if PML 
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may specifically inhibit the growth of SCLC. SCLC cell lines 
that those do not express PML will be transfected with the 
wild-type PML gene as well as with the vector alone. The PML 
gene was previously cloned in the BamH1 site of the 
expression vector,pSG5 (stratagene, La Jolla, CA)(19). 
Alternatively we may subclone the PML cDNA into vectors 
with inducible promoter such as the Tet-on system of 
Strategene Inc., or with the MEM-neo-blue vector. The 
inducible promoter will be useful to test genes that are 
absolutely essential for cell survival and cell growth. The 
transfected cells will be analyzed for inhibition of growth, in 
culture and in nude mice. Cell growth will be monitored by [H； 
thymidine incorporation, cell counts or by flow cytometry. As 
control the PML gene will also be transfected into 
adenocarcinoma cells which should be less affected. These 
data wjll allow us to conclude if PML is playing a suppressor 
role in SCLC. 
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Table 1A. PML expression in HCC and secondary Liver cancers. 
Tumor types Sample PML PML PML 
(differentiation) | ^ Tumor center peri-tumor Non-tumor 
WD HCC 5 ^ 3++ ^ 
1+/- 2+ 3+ 
^ 
^WD-MD& 6 ^ ^ 1+++ 
MDHCC 1+ 3+ 2++ 
3+A V^ 3+ 
MD-PD & 4 2+++ ^ ^ 
PDHCC 1++ 2+ 2+ 
^J^ 
~~~us HCC 7 1+++ U ?+++ 
1+ 5+ 2++ 
^ V}± 4+ 
Secondary liver 6 1++ H+ 1+++ 
cancer colon 4+ 4+ 4++ 
metastasis ]^  ;|^  ]+ 
Liver cirrhosis 6 -- ~ 2+++ 
4++ 
Normal liver 18 ~ : 14+/-
4-
Footnote: +++ very strong; ++ moderately strong; + moderate; +/- weak or 
partial; - negative. 
WD, well differentiated; MD, moderately differentiated; PD, poorly 
differentiated; US, unspecified. 
Table 1B. PML expression in single and multiple encapsulated lesions 
ofHCC 
Tumor Sample P m i PML positive P j ^ P ^ " ^ 
type No. negative tumor-center negative positive 
tumor-center peri-tumor peri-tumor 
Single 一 14 8(57%) 6(43%) 2(14%) 12(86%) 
Multiple 9 2(22%) 7(78%) 1 ^ % i 8(^9%) 
79 
Table 2. PML expression in human lung cancers. 
Tumor types Sample No. Tumor-center ~~Peri-tumor ~Peri-tumor 
(tumor cells) (tumor cells) (non-tumor 
cells) 
Normal lung 17 — — 1+++ 
13++ 
3+ 
Squamous 12 6+ 4++++ 7+++ 
Cell 3+/- 8+++ 5++ 
Carcinoma ^ 
Adeno-Carcin 10 1++ 1++++ 7+++ 
oma 5+ 6+++ 3++ 
4+/- • 3++ 
~~Small cell 8 ^ ^ 1+++ 
Lung Cancer 6- 6- 3++ 
4+ 
Metastasis 6 2+++ 2+++ 1+++ 
4++ 4++ 4++ 
^ 1 + 
Footnote: ++++ and +++(>20 POD) very strong; ++(10-20 POD) moderately 





Figure 1. Expression of PML in Normal liver, HCC and 
secondary liver cancer. Paraffin sections from tissue samples 
were stained with antibody against PML as described in Methods. 
The antibodies were raised in rabbits with the recombinant PML 
protein. The PML antibody was diluted in 1:2000，and the 2nd 
antibody was a goat-anti-rabbit lgG conjugated with horse radish 
peroxidase(Zynned Lab.). The staining kit was a Histostain-sp kit 
from Zymed Lab, using AEC as chromogen which labeled 
brownish-red for the antigen. (Panel A), normal liver; (Panel B), 























































Figure 2. PML expression in different cell types of cirrhotic 
liver from a chronic hepatitis patient and in liver abscess. 
Tissue samples from liver biopsy of chronic hepatitis patients were 
stained for the expression of PML as described in Methods. (Panel 
A), hepatocytes, (Panel B), lymphocytes of hepatitis tissues. 
(Panel C), bile duct epithelial cells of hepatitis tissues, and (Panel 
D), liver abscess. Liver tissues from abscess were analyzed for 
PML expression as described in Methods (400X). 
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Figure 3. Gradation of expression of PML in a 
single-encapsulated lesion of HCC. A HCC sample of 
single-encapsulated lesion was analyzed for PML expression by 
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Figure 4. Differential expression of PML at the periphery and 
at the center of HCC. High magnification of HCC samples of 
single-encapsulated lesion were analyzed for expression of PML 
as described in Methods. (Panel A), tumor cells at the periphery of 
the tumor with the encapsulated fibrous tissues, (Panel B), tumor 
cells located at a distance of approximately 1 cm from the 
periphery of the tumor (400X). 
» . 
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Figure 5. Expression of PML in normal lung tissues and 
inactivation of PML expression in small cell lung cancer. 
Paraffin sections of lung tissues from normal human subjects were 
immunohistochemically stained with a rabbit polyclonal antibody 
against the recombinant PML protein as described in Methods. 
Panel A, normal lung tissues stained with antibody against PML 
showed the expression from moderately strong (++) to moderate 
(+) in bronchial epithelial cells, pneumocytes, macrophages, 
fibroblast and endothelial cells, indicating PML expression is 
associated with the normal functions of various cell types in the 
lung. Panel B showed small cell lung cancer stained with PML 
antibody(200X). Colour photo: Panel C showed low magnification 
of SCLC stained with antibody against PML(100X). DAB was used 
as a chromogen which labeled the antigen PML as darkish-brown 
in color. The nuclei were stained blue by the counter-staining 
hematoxylin. At lower magnifications, SCLC cells were found to be 
mostly negative for PML expression ranging from (-) to (+/-) in all 
18 samples examined, while the adjacent non-tumor cells 
expression considerable quantities of PML. PML staining was 
» . 
confined to the nucleus as nuclear dots (POD) or nuclear bodies, 
or as a homogeneously stained pattern. Panel D showed higher 
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Figure 6. Enhanced expression of PML in adenocarcinoma 
and squamous cell carcinoma of the lung. Paraffin sections of 
lung cancer tissues were immunohistochemically stained with 
antibodies against PML as described in Methods for Panel A, 
adenocarcinoma (400X); and Panel B, squamous cell carcinoma 
(100X). Color photo: Panel C showed PML expression in 
adenocarcinoma of lung (400X)_ In contrast to SCLC, increased 
expression of PML was found in most of the adenocarcinomas of 
the lung examined. The stainings of PML in more than 15 samples 
of lung adenocarcinoma usually ranged from very strong (+++) to 
moderately strong (++). The epithelia cells surrounding tumor also 
contained increased levels of PML Panel D showed PML 
expression in squamous cell carcinoma (400X). PML expression 
ranged from moderately strong (++) to moderate (+). In addition, 
PML was expressed most strongly in cancer ceils at the periphery 
of the tumor as well as in the surrounding non-tumor cells. 
» , 
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Figure 7. Enhanced expression of PML in metastasis of lung 
cancer. Lung cancers that metastasized to blood vessels (Panel 
A) and to the lymph node (Panel B) were analyzed for PML 
expression as described in Methods (200X). 
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Figure 8. Double staining of PML and with the proliferation 
marker Ki67 or with the macrophage marker KP1 in lung 
cancers. Panel A, SCLC stained with PML antibody (brownish 
red) alone. Panel B, SCLC and Panel C, SCC, double staining with 
antibodies against PML (brownish red dots of nuclear POD 
structure), and the proliferation marker Ki67 (homogeneous dark 
brown staining). Panel D, non-tumor sample of macrophages, 
Panel E, macrophages of SCC, and Panel F, giant cells of SCC. 
Samples were stained with PML and the macrophage specific 
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Figure 9. Expression of PML in HeLa cells and HeLa cells 
transfected with the PML gene 
To further elucidate the function of the suppressor PML, HeLa 
cells and HeLa cells transfected with the PML gene was analyzed. 
These cells were first analyzed for the expression of PML protein. 
Panel A was negative control, Hela cells only were added blocking 
solution as primary antibody for staining (400x). Panel B was also 
negative control, Hela cells were treated with preimmune serum 
(PI) for staining (400x). Panel C, Hela cells were stained with PML 
antibody (diluted in 1:2000). Panel D, Hela-PML cells were stained 
with PML antibody (diluted in 1:2000). Showed increased levels of 
PML expression (400x). The staining kit was Histostain-sp kit from 
Zymed Lad, using AEC as chromogen which labeled brownish-red 
for the antigen showed as panel C and D. These slides was used 
hematoxylin for counterstaining. 
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Figure 10. Altered morphology of the HeLa-PML cell-clones. 
Morphology of HeLa and HeLa-PML cells were photographed as 
described. Panel A is the parental HeLa cells which formed 
monolayer of single cells. The HeLa-PML in Panel B formed 
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Figure 11. Altered growth rate in Hela-PML cells. 
Hela and PML cells were cultured with complete medium in 
standard conditions, count cell number everyday until cell 
confluent as described in Methods. The PML transfected clones 
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Figure 12. Altered rate of cell-death in HeLa cells transfected 
with PML. 
HeLa and HeLa-PML cells were treated with an anti-cancer agent, 
cisplatin at 0，1，5 and 10 ^ig/ml. Cells were incubated at 37°Cfor 
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APPENDIX. Original paper published on European Journal of 
Cancer 
106 
European Journal of Cancer 
Original Paper 
Altered Expression ofthe Growth and Transformation 
Suppressor PML Gene in Human HepatoceUular Carcinomas 
and in Hepatitis Tissues 
J.Y.H. Chan,i W. Chin’i C.-T. Liew,^ K.-S. Chang^ and PJ. Johnson^ 
Departments of ^Clinical Oncology and ^Anatomic and Cellular Pathology, Sir Y.K. Pao Centre for Cancer, 
Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; and ^Division of Laboratory 
Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, U.S.A. 
(Reprintedfrom European JournalofCancer Vol. 34, No. 7, Pages 1015-1022, 1998) 
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Altered Expression of the Growth and Transformation 
Suppressor PML Gene in Human HepatoceUular Carcinomas 
and in Hepatitis Tissues 
J.Y.H. Chan，i W. Chin,i C.-T. Liew,^ K , S . Chang^ and PJ. Johnson^ 
Departments of ^Clinical Oncology and ^Anatomic and Cellular Pathology, Sir Y.K. Pao Centre for Cancer, 
Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong; and ^Division of Laboratory 
Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, U.S.A. 
The promyelocytic leukaemia (PML) gene, which encodes a transformation and growth suppressor, 
was first identified at a chromosomal translocation break point in acute promyelocytic leukaemia. To 
elucidate if PML may be involved in hepatoceUular carcinoma (HCC), the expression of PML was 
analysed using immunohistochemistry in human HCC and hepatitis tissues. Our studies demon-
strated overexpression o f P M L protein in the PML-oncogenic domain (POD) structure in 50®/o o f H C C 
(11/22). Enhanced expression and cytoplasmic localisation of PML was associated with cirrhosis. 
Increased expression of PML was also found in liver abscesses. However, in colon metastasis to the 
liver, the expression of PML was moderate to low, although strong expression was seen in the 
surrounding interstitial ceUs, macrophages and lymphocytes, an indication of the inflammation 
process associated with tumour growth. Most interestingly, strong expression of PML was found in 
neoplastic ceUs at the periphery of the tumours, but progressively decreased in ceUs at the centre of 
the tumours, which may be associated with an altered transform phenotype or apoptosis. The altered 
expression of PML indicates that this nuclear protein may play an important role in ceUular response 
to stress and inflammation, as weU as in compensatory ceU growth. • 1998 Elsevier Science Ltd. AU 
rights reserved 
Key words: suppressor genes, PML, hepatoceUular carcinoma, hepatitis B, gene expression regulation, 
neoplastic 
EurJCancer, Vol. 34, No. 7, pp. 1015-1022, 1998 
INTRODUCTION cells by inactivating the normal functions of PML and reti-
D i S R U P T i O N S OF p r o t o - o n c o g e n e s a n d o n c o s u p p r e s s o r g e n e s n o i c a c i d X r e c e p t o r ( R X R ) p r o t e i n s . 
have been attributed to the pathogenesis of many neoplastic PML is a nuclear phosphoprotein which has been shown 
diseases [1—4]. The promyelocytic leukaemia {PML) gene to inhibit cell growth and the transformed phenotypes of 
encodes a growth and transformation suppressor, and has tumour cells [9-12]. PML has also been found to accumulate 
been identified at the non-random chromosomal transloca- at the border of a nuclear structure, namely the nuclear bod-
tion break point t(15;17)(q22;ql2) of acute promyelocytic ies or PML oncogenic domain (POD) [13-16], In APL cells, 
leukaemia (APL) [5-8]. This translocation event fuses the the PML-RARA fusion protein was found to accumulate into 
PML and the retinoic acid receptor-a (RARA) genes and aberrant microstructures and is able to delocalise some other 
encodes the PML-RARA and RARA-PML fusion proteins, nuclear proteins. Thus, PML is a transcriptional factor that 
PML-RARA apparently exerts a dominant negative effect in has been considered to play a crucial role in the pathogenesis 
of APL. Moreover, there is evidence that PML is involved in 
cell cycle progression and viral replication [9,13-18]. A sig-
Correspondence to J.Y.H. Chan. nificant increase in PML nuclear bodies and a non-aggre-
Received 25 Jul. 1997; revised 3 Nov. 1997; accepted 1 Dec. 1997. gated soluble form was found as cells progress through G 1 
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1016 J.Y.H. Chan et al. 
and S phases of the cell cycle [ 18]. PML is also a member of a 30 mM ammonium hydroxide, the slides were mounted with 
novel family of ring-finger proteins and is structurally related aqueous or permanent mounting medium. The expression of 
to enzymes expressing DNA repair and DNA recombination PML in the POD structure was rated as: + + + , very strong 
activities [15-17]. or >20 POD; + +，strong or 10-20 POD; + , moderate or 
Although reports on PML in other cancers have been 5-10 POD; + / - , weak or partial, or 1-5 POD; and 一, 
documented [17-20], the precise role of PML in regulating negative, 
cell growth and transformed phenotypes of other neoplasias, 
including the hepatocellular carcinomas (HCCs), is still RESULTS 
unclear. HCC accounts for approximately 85% of primary Altered expression of PML in normal liver, HCC and secondary 
malignant tumours of the liver and HCC also shows marked liver tumours 
geographical variation in incidence [21]. In Hong Kong and In normal liver (Figure la) low but detectable levels of 
South-eastern Asia, with an incidence of 25-35/100000, it is PML (14 cases + / - ; 4 cases negative) were found in the 
one of the major cancers in this region, especially in those nuclei of hepatocytes as POD or nuclear bodies, confirming 
with hepatitis B virus infection and/or liver cirrhosis. Our results previously published [19]. Other cells that are known 
laboratories are interested in the aetiology, diagnosis and to express low levels of PML in liver include Kuppfer cells, 
treatment ofneoplastic diseases including HCC [20-23], and activated macrophages, epithelia and endothelial cells [18-
to elucidate if PML resembles other oncosuppressor genes 20]. In HCC samples a 5-10-fold increase in expression of 
such as p53 and Rb, we examined the expression of PML PML was found in the tumour cells. In addition, endothelial 
protein in human tissues of HCC, hepatitis, cirrhosis, liver cells, epithelia, activated macrophages, lymphoid cells and 
abscess and secondary liver cancers. Kuppfer cells were also highly stained positive for PML. As 
shown in Figure 1(b), considerable enhanced expression of 
PATIENTS AND METHODS PML in the nucleus was found in a large number of HCC 
Patients and samples samples. The typical trabecular arrangement with endothe-
All samples were from Hong Kong Chinese patients. lial-lined sinusoids separating the aggregates of tumour cells 
Twenty-two samples of HCC were obtained which included was also observed. Interestingly, in some samples of HCC, a 
five well differentiated HCC, six well to moderately differ- cytoplasmic localisation of PML was observed. To determine 
entiated or moderately differentiated HCC, four moderately if the enhanced expression was specific to primary liver neo-
to poorly or poorly differentiated HCC and seven unspecified plasia, several samples of secondary liver cancers were inves-
or recurrent HCC. Of these, 14 were related to chronic tigated. As shown in Figure 1(c), the expression of PML in 
hepatitis B virus infection. As control tissues, six samples of secondary liver cancers, which were colon adenocarcinomas 
secondary liver tumours (metastatic adenocarcinoma from that metastasised to the liver, usually ranged from moderate 
colon), six samples of chronic hepatitis infected liver with to low but still detectable. However, the staining was mostly 
cirrhosis and two samples from liver abscesses were used. confined to the nucleus as nuclear bodies or PODs. In con-
Eighteen normal samples of liver tissue (from autopsy or trast, liver cells surrounding the cancer contained increased 
transplanted liver) were also studied. levels of PML, both in the nucleus and in the cytoplasm. In 
addition, the expression of PML was also found to increase in 
Immunohistochemical staining the infiltrating lymphocytes, macrophages and fibroblast 
Immunohistochemical staining was analysed using affinity- cells, 
purified rabbit antibody raised against the recombinant PML 
protein, as described previously [9-12]. In brief, tissue sam- Increased expression ofPML in chronic hepatitis tissues 
ples were obtained from resected livers and tumours, and Although the precise relationship between hepatitis and 
were immediately fixed in 4% paraformaldehyde in phos- liver cirrhosis and HCC is still uncertain, it is believed that 
phate-buffered saline (PBS) for 24 h and embedded in paraf- chronic hepatitis and cirrhosis are premalignant lesions. To 
fin. Tissue sections were prepared in polylysine coated slides determine if the increased expression of PML is also asso-
and all steps were performed at room temperature. Slides ciated with precancerous conditions of HCC, cirrhotic liver 
were first heated at 60°C in an oven. After dewaxing with samples of patients with chronic hepatitis were immuno-
xylene and rehydration with gradient alcohols, the slides were stained with PML. As shown in Figure 2(a)，strong nuclear 
heated to boiling in lOmM sodium citrate buffer pH 6.8 for staining of PML was found in the hepatocytes ofthe hepatitis 
lOmin in a microwave oven. After treatment with 3% tissues, similar to the non-tumour area of HCC slides which 
hydrogen peroxide in methanol to inactivate the endogenous were usually cirrhotic in nature. However, cytoplasmic loca-
peroxidase activity, the samples were blocked with the block- lisation of PML was also observed in hepatitis tissues. In 
ing solution which consisted of 5% bovine serum albumin addition, infiltrating lymphocytes and macrophages sur-
(BSA) in PBS, for 20 min, and then incubated with the first rounding cirrhotic liver also showed strong expression of 
antibody, PML antibody (1:2000 in blocking solution), for PML, which indicates that the enhanced expression of PML 
1-2 h at room temperature. After washing three to four times occurs in a variety of cell types. The staining was mostly 
with PBS, the samples were incubated with each secondary homogeneous, uniformly distributed and with a diffuse pat-
antibody (goat anti-rabbit IgG-conjugated with biotin and tem. The surrounding Kupffer cells, which are one of the 
then with avidin-conjugated with horse radish peroxidase, sinusoidal endothelial cells and the resident macrophages in 
BioGenex Lab., California, U.S.A.) for 30 min, and washed the liver, were also stained strongly by the antibody against 
with PBS after each step. The slides were developed with PML. Kupffer cells have important roles in the biological 
substrates for peroxidase (AEC or DAB reagents, Histostain defence mechanism and in the maintenance ofhomeostasis of 
kit, Zymed Lab, S. San Francisco, California, U.S.A.). After the body. As shown in Figure 2(b), strong PML staining was 
counterstaining with haematoxylin and briefly washing with observed in lymphocytes surrounding cirrhotic liver nodules. 
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Table 1. PML expression in hepatocellular carcinoma (HCC) and secondary liver cancers 
PML staining 
Sample no. Tumour centre Peri-tumour Non-tumour 
Hepatocellular carcinoma 
Well diflferentiated 5 + ( « = 3) ++(« = 3) +++ (n = 2) 
+/_ (n=l) + (n = 2) ++ (n = 3) 
-(«=1) 
Well to moderately or moderately 6 ++ {n = 2) ++ (« = 2) +++ (« = 1) 
+ (n= 1) + (n = 3) ++ (n = 2) 
+/_ (n = 3) + / - (n= 1) + (n = 3) 
Moderately to poor or poorly 4 +++ (n = 2) ++ (n = 2) ++ (n = 2) 
++ (n=l) + (n = 2) + (n = 2) 
+/- (w=l) 
Unspecified 7 + + + ( « = 1 ) ++(w=l) +++(”=1) 
+ {n= 1) + {n = 5) ++ (n = 2) 
+/- (n = 5) + / - (w= 1) + (n = 4) 
Secondary liver colon metastasis 6 ++ (n= 1) + + ( « = 1 ) +++ (n = 1) 
+ (n = 4) + (n = 4) ++ (n = 4) 
-(n= 1) - (n= 1) + ( n = 1) 
Liver cirrhosis 6 一 — +++ (n = 2) 
++ (n = 4) 
Normal liver 18 — — +/—(«=14) 
- ( n = 4) 
+++, very strong, ++, strong, +，moderate; + / - ’ weak or partial; - ’ negative. 
In addition, the expression ofPML in bile duct epithelial cells dated with liver cirrhosis and HCC. Since the non-tumori-
of hepatitis tissues was found to increase significantly com- genic regions of the HCC samples were mostly cirrhotic in 
pared with control liver. As shown in Figure 2(c), epithelial nature, it is not surprising that the expression of PML was 
cells associated with the bile duct were strongly stained for also strong. However, the expression of PML appears to have 
PML, indicating that its enhanced expression is present in no direct correlation with differentiation, although an inverse 
several cell types. To determine if the enhanced PML correlation was found in unspecified differentiation HCC at 
expression is also associated with other pathological condi- the tumour centxe (only two ofseven samples showed positivity). 
tions of the liver, samples of liver abscess were analysed. 
Interestingly, increased expression of PML was also observed Differential expression ofPML at the periphery and at the centre 
in certain cells. As shown in Figure 2(d), the layer of cells ofsingle encapsulated HCC 
surrounding the abscess contained increased levels o fPML as To determine whether there is a difference in the expres-
compared with neighbouring cells. These results strongly sion of PML in the peri-tumoral regions and at the centre of 
indicate that enhanced PML expression is associated with the the tumour, HCCs with large and single encapsulated lesions 
process of inflammation and/or cell death, most likely with were further analysed for the expression of PML. In 
the compensatory cell growth during cell injury. Figure 3(a), a region between the periphery and the tumour 
The number of HCCs and secondaries analysed and their centre of a HCC is shown. The PML staining pattern appears 
PML expression are shown in Table 1. Five cases of well to have a gradation of intensity ranging from strong in the 
differentiated HCC contained mostly moderate (+) to weak peri-tumoral region to weaker expression towards the centre 
(+ / - ) PML expression at the tumour centre, while strong of the tumour. Enhanced expression of PML was found in 
(+ + ) to moderate (+) PML was found in peri-tumoral the neoplastic cells at the periphery ofthe HCC (Figure 3b), 
regions. The surrounding non-tumorous tissues, which were which is apparently the site of rapid proliferation and expan-
mostly cirrhotic, expressed high PML (+ + + to + + Table 1). sion. The surrounding encapsulated fibrous layers of con-
Similar results were found with the well to moderately or nective tissue stroma contained numerous fibroblasts and 
moderately differentiated HCC. For the moderate to poor or lymphocytes that overexpressed PML (data not shown), 
poorly differentiated HCC and the unspecified differentiation However, the expression of PML progressively decreased to 
HCC, slightly more intense staining of PML was observed. moderate or very low levels at the centre of the tumour 
Most tumour cells in peri-tumoral regions showed strong (Figure 3c). In contrast, PML expression in HCCs with 
(+ +) or moderate (+) PML expression. The majority of multi-encapsulated lesions or with numerous fibrosis encap-
secondary liver cancers from colon metastasis only showed sulation was usually high and did not show a gradient of 
moderate expression (four of six were +) in both tumour diminishing expression (data not shown). Interestingly, a dif-
centre and at peri-tumoral regions. The surrounding non- ferential expression of PML was found in single versus multi-
mmoral regions of most liver cancers showed very strong encapsulated regions of HCC (Table 2). A large number of 
(+ + + {n = 2) or + + {n = 6)) expression of PML. For cir- single encapsulated lesions of HCC (8 of 14, 57%) showed 
rhosis, two samples were + + + while four samples showed low or no expression of PML in the tumour centre, while the 
+ + expression. In contrast, the 18 normal livers all showed majority of multiple lesions (78%) showed positive or 
weak/partial or negative expression (14 + / - and f o u r - ) . enhanced PML expression. These results, taken together, 
These data indicate that increased PML expression is asso- indicate that PML expression in the liver and in HCC is 
^ 
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Table 2. PML expression in single and multiple encapsulated matchmaker to recruit or sequester other proteins in or out of 
lesions of hepatocellular carcinoma the POD. Nevertheless, PML may play an important role in 
the loss of growth control and in the oncogenesis of many 
PMLstaining cancers. 
Tumour centre Peri-tumoral The gradient of expression of PML found in HCC is 
somewhat unexpected, but not surprising. Many regulatory 
Tumour types Negative Positive Negative Positive molecules show a gradient of expression in tissues, cells and 
Single (n=14) 8(57%) 6(43%) 2(14%) 12 (86%) e™bryos. PMLexpression in HCC isprobably analogous to 
Multiple (« = 9) 2(22%) 7(78%) 1 ( 1 1 % ) 8 (89%) the oxygen gradient in tumours m which the tumour centres 
are mostly hypoxic while the peri-tumoral regions are oxygen-
rich because of the availability of ample blood supplies. 
Although the exact reason for the gradient of PML expression 
rather complex, and it is apparently associated with mediators is not known, it could be an indication that cells at the peri-
in the micro-environment of the peri-tumoral region. tumoral regions and those at tumour centres belong to dif-
ferent stages of the tumorigenic process. In addition, cyto-
DISCUSSION kines and lymphokines are known to be produced by cells in 
Cancer development, including that o fHCC, appears to be the inflammatory regions, and since PML expression can be 
a multistage multi-hit process in which normal cells progress induced by cytokines, i.e. interferons, PML may be activated 
to malignant neoplasia through an accumulation of genetic in both the tumour and non-tumour cells at the peri-tumoral 
and epigenetic changes [l-7]. Many of these genomic and regions. Thus, an alternative explanation is that the gradient 
phenotypic alterations occur in proto-oncogenes and onco- of expression of PML in tumours is a reflection of the differ-
suppressor genes which are known to affect cellular pro- ential concentration of secreted cytokine(s) at different 
liferation and signal transductions [l-4]. In addition, there is regions of the tumours. 
considerable evidence supporting the importance of onco- Our data on the enhanced nuclear and cytoplasmic 
suppressor genes in regulating cell growth and differentiation. expression of PML in HCC and hepatitis with an antibody 
Some of the tumour suppressor genes are also responsible for raised against the recombinant protein are in general agree-
protecting cells from the deleterious effects of DNA damage ment with those published previously [18-20], indicating that 
and xenobiotics by arresting cell cycle progression and by PML displays an altered expression pattern during human 
triggering programmed cell death [3,4]. The p53 gene is a oncogenesis. The studies previously reported have used a 
prototype example in which mutated forms of the gene have polyclonal antibody raised against the recombinant PML 
been found in many tumour types [4]. Overexpression oip53 protein, and the 5E10 monoclonal antibody which was pre-
as a result of increased stability of the protein has been found viously shown to recognise nuclear matrix-associated nuclear 
in cancer cells that contained the mutated gene，or had p53 bodies. We also confirmed the results of Terris and co-work-
protein sequestered and inactivated by viral proteins. Muta- ers [19] who showed that PML expression is enhanced in 
tions in specific regions of the gene may contribute to the several cell types of the inflammatory tissues in liver because 
aberrant localisation of the gene product [3]. Since not all chronic inflammation and cell injury induce signals for apop-
tumours contain defective p53, it is believed that other tosis and regeneration, affecting cell cycle progression and the 
molecules that regulate cell growth and differentiation may be expression of PML. Inflammatory cells may increase the 
involved in the loss of growth control during oncogenesis. secretion of growth factors, cytokines and hormones. These 
PML has been found to accumulate at the border of a nuclear biological mediators may in turn induce the expression of 
structure, namely the nuclear bodies or POD [10，11,14-16]. cellular stress responsive genes and growth regulatory genes, 
PML has been found to be co-localised with several proteins, including PML, in neighbouring hepatocytes. In addition, we 
including Sp-100, NDP55, PIC 1, Int-6 and possibly others, observed that 50% of HCC (11/22) overexpressed PML, 
in the POD structure [24-27]. PML may play a role in viral which is similar to the results of Terris and co-workers [19] 
replication [13,14]. During adenovirus infection, the of 78% (18/23) PML positivity. However, heterogeneous 
immediate early viral proteins ElB 55 kDa and E4-ORF3 nuclear expression of PML protein has also been reported in 
11 kDa are targeted to the POD structure [13]. The Epstein- normal and neoplastic tissues [20]. Carcinomas of the larynx 
Barr virus (EBV)-encoded protein EBNA-5 has been shown and skin were reported to express high levels of PML, while 
to co-localise with PML in the POD structure in lympho- the expression of PML in oat cell carcinomas of the lung were 
blastoid cells [15], while the immediate-early protein (Vmwl reported to be low. The mechanism for the differential 
10) of the herpes simplex virus (HSV) could interact with expression of PML in various types of tumours is at present 
PML [16]. Whether the HBV contains a gene, the product of unknown. Although some of these can be attributed to tissue-
which may interact with PML, is at present unknown, specific expression, our data, showing the differential expres-
Moreover, the specific target genes for PML are also not sion of PML at various sites of a single encapsulated lesion of 
known, but the gene products that co-localise with PML in HCC，perhaps could resolve some of the apparent dis-
the POD structure may represent some of the target genes of crepancies and raise a cautionary note for the analysis of 
PML, or these proteins may regulate PML. However, the partial specimens. In contrast, multi-encapsulated lesions of 
precise function of PML and the POD structure is also HCC or tumours with numerous encapsulation and peri-
unclear. One hypothesis put forth by Maul and co-workers tumoral fibrosis usually expressed high levels of PML, and 
[28] is that the nuclear bodies or POD may represent storage did not show a gradient of decreasing expression. Apparently 
sites of certain matrix proteins readily accessible throughout cells at the periphery are rapidly dividing and express high 
the chromatin in response to stress or other effectors that levels of PML, while cells at the tumour centre of the 
induce global nuclear changes. Thus, PML may act as a tumours, which has limited blood supply, are usually 
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